DK164845B - Farmaceutiske midler omfattende polypeptider med kontinuerlig frigoerelse - Google Patents

Farmaceutiske midler omfattende polypeptider med kontinuerlig frigoerelse Download PDF

Info

Publication number
DK164845B
DK164845B DK059182A DK59182A DK164845B DK 164845 B DK164845 B DK 164845B DK 059182 A DK059182 A DK 059182A DK 59182 A DK59182 A DK 59182A DK 164845 B DK164845 B DK 164845B
Authority
DK
Denmark
Prior art keywords
weight
polylactide
polypeptide
glycolide
pharmaceutical agent
Prior art date
Application number
DK059182A
Other languages
Danish (da)
English (en)
Other versions
DK59182A (da
Inventor
Francis Gowland Hutchinson
Original Assignee
Ici Plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10519727&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK164845(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ici Plc filed Critical Ici Plc
Publication of DK59182A publication Critical patent/DK59182A/da
Priority to DK199200455A priority Critical patent/DK174120B1/da
Publication of DK164845B publication Critical patent/DK164845B/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A61K9/204—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7007—Drug-containing films, membranes or sheets
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D319/00—Heterocyclic compounds containing six-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D319/10—1,4-Dioxanes; Hydrogenated 1,4-dioxanes
    • C07D319/12—1,4-Dioxanes; Hydrogenated 1,4-dioxanes not condensed with other rings
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G63/00—Macromolecular compounds obtained by reactions forming a carboxylic ester link in the main chain of the macromolecule
    • C08G63/02—Polyesters derived from hydroxycarboxylic acids or from polycarboxylic acids and polyhydroxy compounds
    • C08G63/06—Polyesters derived from hydroxycarboxylic acids or from polycarboxylic acids and polyhydroxy compounds derived from hydroxycarboxylic acids
    • C08G63/08—Lactones or lactides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S930/00—Peptide or protein sequence
    • Y10S930/01—Peptide or protein sequence
    • Y10S930/28—Bound to a nonpeptide drug, nonpeptide label, nonpeptide carrier, or a nonpeptide resin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Polymers & Plastics (AREA)
  • Neurosurgery (AREA)
  • Dermatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Polyesters Or Polycarbonates (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
  • Biological Depolymerization Polymers (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Polyethers (AREA)
DK059182A 1981-02-16 1982-02-11 Farmaceutiske midler omfattende polypeptider med kontinuerlig frigoerelse DK164845B (da)

Priority Applications (1)

Application Number Priority Date Filing Date Title
DK199200455A DK174120B1 (da) 1981-02-16 1992-04-03 Poly(lactid-co-glycol)polymer omfattende mindst 25 mol% mælkesyreenheder og op til 75 mol% glycosyreenheder samt fremgangsmåde til fremstilling heraf

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB8104734 1981-02-16
GB8104734 1981-02-16

Publications (2)

Publication Number Publication Date
DK59182A DK59182A (da) 1982-08-17
DK164845B true DK164845B (da) 1992-08-31

Family

ID=10519727

Family Applications (1)

Application Number Title Priority Date Filing Date
DK059182A DK164845B (da) 1981-02-16 1982-02-11 Farmaceutiske midler omfattende polypeptider med kontinuerlig frigoerelse

Country Status (20)

Country Link
US (2) US5004602A (fr)
EP (1) EP0058481B2 (fr)
JP (4) JPS57150609A (fr)
AT (1) ATE22535T1 (fr)
AU (3) AU560829B2 (fr)
CA (1) CA1169090A (fr)
DE (1) DE3273501D1 (fr)
DK (1) DK164845B (fr)
ES (1) ES8307845A1 (fr)
FI (1) FI80594B (fr)
GR (1) GR76791B (fr)
HK (1) HK107890A (fr)
HU (2) HU199695B (fr)
IE (1) IE52535B1 (fr)
MY (1) MY101545A (fr)
NO (1) NO162103C (fr)
NZ (1) NZ199732A (fr)
PT (1) PT74434B (fr)
YU (1) YU44066B (fr)
ZA (1) ZA82565B (fr)

Families Citing this family (1057)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE52535B1 (en) * 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions
US4637905A (en) * 1982-03-04 1987-01-20 Batelle Development Corporation Process of preparing microcapsules of lactides or lactide copolymers with glycolides and/or ε-caprolactones
FR2537980B1 (fr) * 1982-12-17 1986-12-19 Sandoz Sa Derives d'acides hydroxycarboxyliques oligomeres, leur preparation et leur utilisation
US4652443A (en) * 1983-06-07 1987-03-24 Japan Atomic Energy Research Institute Slow-release composite and process for producing the same
CA1196864A (fr) * 1983-06-10 1985-11-19 Mattheus F.A. Goosen Composes d'insuline implantable et injectable a liberation regulee
CH656884A5 (de) * 1983-08-26 1986-07-31 Sandoz Ag Polyolester, deren herstellung und verwendung.
CH661206A5 (fr) * 1983-09-23 1987-07-15 Debiopharm Sa Procede pour la preparation d'un medicament destine au traitement de maladies hormonodependantes.
JPS6097918A (ja) * 1983-11-01 1985-05-31 Sumitomo Chem Co Ltd インタ−フエロン持続性製剤
JPS60100516A (ja) * 1983-11-04 1985-06-04 Takeda Chem Ind Ltd 徐放型マイクロカプセルの製造法
JPS60181029A (ja) * 1984-02-29 1985-09-14 Toyo Jozo Co Ltd 徐放性製剤の製法
GB8416234D0 (en) * 1984-06-26 1984-08-01 Ici Plc Biodegradable amphipathic copolymers
CA1256638A (fr) * 1984-07-06 1989-06-27 Motoaki Tanaka Polymere, et sa production
US4666885A (en) * 1985-02-08 1987-05-19 Fernand Labrie Combination therapy for treatment of female breast cancer
US4760053A (en) * 1984-08-02 1988-07-26 Fernand Labrie Combination therapy for selected sex steroid dependent cancers
US4880635B1 (en) * 1984-08-08 1996-07-02 Liposome Company Dehydrated liposomes
DE3434345A1 (de) * 1984-09-19 1986-03-27 Hoechst Ag, 6230 Frankfurt Verwendung von (alpha)-interferonen zur bekaempfung von durchfaellen
DE3678308D1 (de) * 1985-02-07 1991-05-02 Takeda Chemical Industries Ltd Verfahren zur herstellung von mikrokapseln.
FR2581544B1 (fr) * 1985-05-10 1989-11-03 Univ Melbourne Procede pour provoquer une ovulation chez les juments et vehicule pharmaceutique associe
US5137874A (en) * 1985-07-29 1992-08-11 American Cyanamid Co. Partially coated C10 -C20 fatty acid salts of peptides having molecular weights up to about 5,000
US5169633A (en) * 1985-07-29 1992-12-08 American Cyanamid Company Continuous release phenylethanolamine derivative compositions
US5059422A (en) * 1985-07-29 1991-10-22 American Cyanamid Company Continuous release phenylethanolamine derivative compositions
US5102872A (en) * 1985-09-20 1992-04-07 Cetus Corporation Controlled-release formulations of interleukin-2
US4643191A (en) * 1985-11-29 1987-02-17 Ethicon, Inc. Crystalline copolymers of p-dioxanone and lactide and surgical devices made therefrom
JPH0725688B2 (ja) * 1986-03-31 1995-03-22 住友製薬株式会社 Ｃｓｆ徐放性製剤
GB8609537D0 (en) * 1986-04-18 1986-05-21 Ici Plc Polyesters
EP0248531A3 (fr) * 1986-05-02 1988-09-28 Southern Research Institute Acides nucléiques encapsulés
CA1257199A (fr) * 1986-05-20 1989-07-11 Paul Y. Wang Preparation contenant une substance macromoleculaire ayant des proprietes biologiques liberee pendant plusieurs mois in vivo
US4962091A (en) * 1986-05-23 1990-10-09 Syntex (U.S.A.) Inc. Controlled release of macromolecular polypeptides
US6150328A (en) 1986-07-01 2000-11-21 Genetics Institute, Inc. BMP products
JPH0725689B2 (ja) * 1986-10-07 1995-03-22 中外製薬株式会社 顆粒球コロニ−刺激因子を含有する徐放性製剤
US6024983A (en) * 1986-10-24 2000-02-15 Southern Research Institute Composition for delivering bioactive agents for immune response and its preparation
US4981696A (en) * 1986-12-22 1991-01-01 E. I. Du Pont De Nemours And Company Polylactide compositions
DE3701625A1 (de) * 1987-01-21 1988-08-04 Boehringer Ingelheim Kg Perorale arzneimittelzubereitung mit verzoegerter wirkstofffreigabe
DE3710175A1 (de) * 1987-02-12 1988-08-25 Hoechst Ag Mehrteilige implantierbare arzneizubereitung mit langzeitwirkung
AU606383B2 (en) * 1987-03-06 1991-02-07 Research Triangle Institute Polymer blends for selective biodegradability
US5028430A (en) * 1987-05-08 1991-07-02 Syntex (U.S.A.) Inc. Delivery systems for the controlled administration of LHRH analogs
US5000886A (en) * 1987-05-26 1991-03-19 American Cyanamid Company Silicone-hardened pharmaceutical microcapsules and process of making the same
DE3822557C2 (de) * 1987-07-10 1998-07-02 Ciba Geigy Ag Arzneimittel, enthaltend Somatostatine
GB8716324D0 (en) * 1987-07-10 1987-08-19 Sandoz Ltd Organic compounds
US4866226A (en) * 1987-07-13 1989-09-12 Mitsubishi Denki Kabushiki Kaisha Multi-phase circuit breaker employing arc extinguishing apparatus
JPH0613602B2 (ja) * 1987-07-14 1994-02-23 三井東圧化学株式会社 ｄ▲ｌ▼−乳酸−グリコール酸共重合物の製造方法
US4897268A (en) * 1987-08-03 1990-01-30 Southern Research Institute Drug delivery system and method of making the same
US5212154A (en) * 1987-08-14 1993-05-18 Akzo N.V. Preparation for treating complications in diabetes
NZ226171A (en) * 1987-09-18 1990-06-26 Ethicon Inc Gel formulation containing polypeptide growth factor
US5457093A (en) * 1987-09-18 1995-10-10 Ethicon, Inc. Gel formulations containing growth factors
GB2209937B (en) * 1987-09-21 1991-07-03 Depiopharm S A Water insoluble polypeptides
US5187150A (en) * 1987-10-14 1993-02-16 Debiopharm S.A. Polyester-based composition for the controlled release of polypeptide medicinal substances
JP2670680B2 (ja) * 1988-02-24 1997-10-29 株式会社ビーエムジー 生理活性物質含有ポリ乳酸系微小球およびその製造法
US4902515A (en) * 1988-04-28 1990-02-20 E. I. Dupont De Nemours And Company Polylactide compositions
FR2634770B1 (fr) * 1988-07-29 1990-10-05 Rhone Poulenc Chimie Composition polyester erodable contenant de l'iode pour le traitement des eaux
US5216050A (en) * 1988-08-08 1993-06-01 Biopak Technology, Ltd. Blends of polyactic acid
US6323307B1 (en) 1988-08-08 2001-11-27 Cargill Dow Polymers, Llc Degradation control of environmentally degradable disposable materials
US5444113A (en) * 1988-08-08 1995-08-22 Ecopol, Llc End use applications of biodegradable polymers
US5502158A (en) * 1988-08-08 1996-03-26 Ecopol, Llc Degradable polymer composition
US5252642A (en) * 1989-03-01 1993-10-12 Biopak Technology, Ltd. Degradable impact modified polyactic acid
US5424346A (en) * 1988-08-08 1995-06-13 Ecopol, Llc Biodegradable replacement of crystal polystyrene
US5180765A (en) * 1988-08-08 1993-01-19 Biopak Technology, Ltd. Biodegradable packaging thermoplastics from lactides
US5250584A (en) * 1988-08-31 1993-10-05 G-C Dental Industrial Corp. Periodontium-regenerative materials
US5633002A (en) * 1988-10-04 1997-05-27 Boehringer Ingelheim Gmbh Implantable, biodegradable system for releasing active substance
US5247013A (en) * 1989-01-27 1993-09-21 Mitsui Toatsu Chemicals, Inc. Biocompatible polyester and production thereof
US4990336A (en) * 1989-02-08 1991-02-05 Biosearch, Inc. Sustained release dosage form
US5116964A (en) 1989-02-23 1992-05-26 Genentech, Inc. Hybrid immunoglobulins
ZA901847B (en) * 1989-03-10 1991-10-30 Endorecherche Inc Combination therapy for the treatment of estrogen sensitive diseases
NZ234227A (en) * 1989-06-30 1991-08-27 Smithkline Beecham Corp Delayed release dosage form
AU5856090A (en) * 1989-07-07 1991-02-06 Endorecherche Inc. Androgen derivatives for use in the inhibition of sex steroid activity
ATE230994T1 (de) * 1989-07-07 2003-02-15 Endorech Inc Methode zur behandlung androgenbedingter krankheiten
HU221294B1 (en) * 1989-07-07 2002-09-28 Novartis Ag Process for producing retarde compositions containing the active ingredient in a polymeric carrier
US5538739A (en) * 1989-07-07 1996-07-23 Sandoz Ltd. Sustained release formulations of water soluble peptides
PH30995A (en) * 1989-07-07 1997-12-23 Novartis Inc Sustained release formulations of water soluble peptides.
US5225205A (en) * 1989-07-28 1993-07-06 Debiopharm S.A. Pharmaceutical composition in the form of microparticles
CH679207A5 (fr) * 1989-07-28 1992-01-15 Debiopharm Sa
US5439688A (en) * 1989-07-28 1995-08-08 Debio Recherche Pharmaceutique S.A. Process for preparing a pharmaceutical composition
EP0423484B1 (fr) * 1989-10-16 1993-11-03 PCD-Polymere Gesellschaft m.b.H. Comprimé à libération retardée
US5126147A (en) * 1990-02-08 1992-06-30 Biosearch, Inc. Sustained release dosage form
US6517859B1 (en) 1990-05-16 2003-02-11 Southern Research Institute Microcapsules for administration of neuroactive agents
WO1991017772A1 (fr) * 1990-05-16 1991-11-28 Southern Research Institute Dopamine administree par liberation regulee et son utilisation pour stimuler la croissance de fibres nerveuses
CA2046830C (fr) * 1990-07-19 1999-12-14 Patrick P. Deluca Systeme d'administration des medicaments comprenant une interaction entre une proteine ou une polypeptide et un polymere hydrophobe biodegradable
IE912365A1 (en) * 1990-07-23 1992-01-29 Zeneca Ltd Continuous release pharmaceutical compositions
US5620959A (en) * 1990-07-31 1997-04-15 Glaxo Wellcome Inc. Bombesin antagonists
GB9016885D0 (en) * 1990-08-01 1990-09-12 Scras Sustained release pharmaceutical compositions
US6353030B1 (en) 1990-08-01 2002-03-05 Novartis Ag Relating to organic compounds
ZA918168B (en) * 1990-10-16 1993-04-14 Takeda Chemical Industries Ltd Prolonged release preparation and polymers thereof.
US5342557A (en) * 1990-11-27 1994-08-30 United States Surgical Corporation Process for preparing polymer particles
US7285531B1 (en) * 1991-04-10 2007-10-23 Acorda Therapeutics, Inc. Method for prophylaxis or treatment of a nervous system, pathophysiological condition involving a glial growth factor sensitive cell by administration of a glial growth factor
US5403595A (en) * 1991-05-07 1995-04-04 Dynagen, Inc. Controlled, sustained release delivery system for smoking cessation
US5486362A (en) * 1991-05-07 1996-01-23 Dynagen, Inc. Controlled, sustained release delivery system for treating drug dependency
HU222501B1 (hu) * 1991-06-28 2003-07-28 Endorecherche Inc. MPA-t vagy MGA-t tartalmazó nyújtott hatóanyag-felszabadulású gyógyászati készítmény és eljárás előállítására
ZA924811B (en) * 1991-06-28 1993-12-29 Endorecherche Inc Controlled release systems and low dose androgens
CH683149A5 (fr) * 1991-07-22 1994-01-31 Debio Rech Pharma Sa Procédé pour la préparation de microsphères en matériau polymère biodégradable.
WO1993009229A1 (fr) 1991-11-04 1993-05-13 Genetics Institute, Inc. Proteines heterodimeres morphogenetiques d'os de recombinaison, compositions et procedes d'utilisation
US6013853A (en) * 1992-02-14 2000-01-11 The University Of Texas System Continuous release polymeric implant carrier
US5876452A (en) * 1992-02-14 1999-03-02 Board Of Regents, University Of Texas System Biodegradable implant
US5912015A (en) * 1992-03-12 1999-06-15 Alkermes Controlled Therapeutics, Inc. Modulated release from biocompatible polymers
US5656297A (en) * 1992-03-12 1997-08-12 Alkermes Controlled Therapeutics, Incorporated Modulated release from biocompatible polymers
DE69311538D1 (de) * 1992-03-12 1997-07-17 Alkermes Inc Acth enthaltende mikrokugeln mit gesteuerter abgabe
US5429822A (en) * 1992-03-13 1995-07-04 Cambridge Scientific, Inc. Biodegradable bursting release system
US5780051A (en) * 1992-04-02 1998-07-14 Dynagen, Inc. Methods and articles of manufacture for nicotine cessation and monitoring nicotine use
UA35589C2 (uk) * 1992-05-21 2001-04-16 Андорешерш Інк. ІНГІБІТОРИ ТЕСТОСТЕРОН 5-<font face="Symbol">a</font>-РЕДУКТАЗИ, ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ ТА СПОСІБ ІНГІБУВАННЯ АКТИВНОСТІ ТЕСТОСТЕРОН 5-<font face="Symbol">a</font>-РЕДУКТАЗИ
GB9211268D0 (en) * 1992-05-28 1992-07-15 Ici Plc Salts of basic peptides with carboxyterminated polyesters
US5674534A (en) * 1992-06-11 1997-10-07 Alkermes, Inc. Composition for sustained release of non-aggregated erythropoietin
US20030035845A1 (en) * 1992-06-11 2003-02-20 Zale Stephen E. Composition for sustained release of non-aggregated erythropoietin
US5716644A (en) * 1992-06-11 1998-02-10 Alkermes, Inc. Composition for sustained release of non-aggregated erythropoietin
JP2651320B2 (ja) * 1992-07-16 1997-09-10 田辺製薬株式会社 徐放性マイクロスフェア製剤の製造方法
FR2693905B1 (fr) * 1992-07-27 1994-09-02 Rhone Merieux Procédé de préparation de microsphères pour la libération prolongée de l'hormone LHRH et ses analogues, microsphères et formulations obtenues.
US5922340A (en) 1992-09-10 1999-07-13 Children's Medical Center Corporation High load formulations and methods for providing prolonged local anesthesia
US5281419A (en) * 1992-09-28 1994-01-25 Thomas Jefferson University Biodegradable drug delivery system for the prevention and treatment of osteomyelitis
CA2150803C (fr) * 1992-12-02 2006-01-31 Henry Auer Hormone de croissance a liberation controlee qui contient des microspheres
TW333456B (en) * 1992-12-07 1998-06-11 Takeda Pharm Ind Co Ltd A pharmaceutical composition of sustained-release preparation the invention relates to a pharmaceutical composition of sustained-release preparation which comprises a physiologically active peptide.
UA61046C2 (en) 1992-12-07 2003-11-17 Takeda Chemical Industries Ltd Sustained-release preparation and method for its manufacture
US5863985A (en) * 1995-06-29 1999-01-26 Kinerton Limited Ionic molecular conjugates of biodegradable polyesters and bioactive polypeptides
US6221958B1 (en) 1993-01-06 2001-04-24 Societe De Conseils De Recherches Et D'applications Scientifiques, Sas Ionic molecular conjugates of biodegradable polyesters and bioactive polypeptides
DK0678018T3 (da) * 1993-01-06 2003-04-28 Kinerton Ltd Ion molekylærkonjugater af bionedbrydelige polyestere og bioaktive polypeptider
US5672659A (en) * 1993-01-06 1997-09-30 Kinerton Limited Ionic molecular conjugates of biodegradable polyesters and bioactive polypeptides
US5456917A (en) * 1993-04-12 1995-10-10 Cambridge Scientific, Inc. Method for making a bioerodible material for the sustained release of a medicament and the material made from the method
US5569467A (en) * 1993-05-15 1996-10-29 Societe De Conseils De Recherches Et D'applications (S.C.R.A.S.) Process for the preparation of microballs and microballs thus obtained
GB9310030D0 (en) * 1993-05-15 1993-06-30 Scras Dry processed particles and process for the preparation of the same
US6440457B1 (en) 1993-05-27 2002-08-27 Alza Corporation Method of administering antidepressant dosage form
US5635216A (en) * 1993-12-16 1997-06-03 Eli Lilly And Company Microparticle compositions containing peptides, and methods for the preparation thereof
CA2163860A1 (fr) * 1993-06-30 1995-01-12 Chung C. Hsu Methode de preparation de liposomes
EP0723402B1 (fr) 1993-08-30 2010-08-18 Baylor College Of Medicine Inhibiteurs de synthese d'adn derives de cellules senescentes
US6291206B1 (en) 1993-09-17 2001-09-18 Genetics Institute, Inc. BMP receptor proteins
US5496923A (en) * 1993-09-20 1996-03-05 Mitsui Toatsu Chemicals, Inc. Purification process of aliphatic polyester
US5643605A (en) * 1993-10-25 1997-07-01 Genentech, Inc. Methods and compositions for microencapsulation of adjuvants
US6080429A (en) * 1993-10-25 2000-06-27 Genentech, Inc. Method for drying microspheres
US6913767B1 (en) 1993-10-25 2005-07-05 Genentech, Inc. Compositions for microencapsulation of antigens for use as vaccines
AU689184B2 (en) 1993-12-07 1998-03-26 Genetics Institute, Llc BMP-12, BMP-13 and tendon-inducing compositions thereof
US5763416A (en) * 1994-02-18 1998-06-09 The Regent Of The University Of Michigan Gene transfer into bone cells and tissues
US6074840A (en) 1994-02-18 2000-06-13 The Regents Of The University Of Michigan Recombinant production of latent TGF-beta binding protein-3 (LTBP-3)
US5942496A (en) * 1994-02-18 1999-08-24 The Regent Of The University Of Michigan Methods and compositions for multiple gene transfer into bone cells
US20020193338A1 (en) * 1994-02-18 2002-12-19 Goldstein Steven A. In vivo gene transfer methods for wound healing
US5962427A (en) * 1994-02-18 1999-10-05 The Regent Of The University Of Michigan In vivo gene transfer methods for wound healing
DE4406172C2 (de) * 1994-02-25 2003-10-02 Sanol Arznei Schwarz Gmbh Polyester
US6551618B2 (en) 1994-03-15 2003-04-22 University Of Birmingham Compositions and methods for delivery of agents for neuronal regeneration and survival
US5877016A (en) 1994-03-18 1999-03-02 Genentech, Inc. Human trk receptors and neurotrophic factor inhibitors
US5708142A (en) 1994-05-27 1998-01-13 Genentech, Inc. Tumor necrosis factor receptor-associated factors
GB9412273D0 (en) 1994-06-18 1994-08-10 Univ Nottingham Administration means
US6093697A (en) * 1994-11-07 2000-07-25 The University Of Virginia Patent Foundation Synthetic insulin mimetic substances
US5607686A (en) * 1994-11-22 1997-03-04 United States Surgical Corporation Polymeric composition
WO1996026716A1 (fr) * 1995-02-28 1996-09-06 Innapharma, Inc. Formulations de microbille d'elcatonine a liberation lente pour le traitement de l'osteoporose
US5665702A (en) * 1995-06-06 1997-09-09 Biomeasure Incorporated Ionic molecular conjugates of N-acylated derivatives of poly(2-amino-2-deoxy-D-glucose) and polypeptides
US6479457B2 (en) 1995-06-06 2002-11-12 Kinerton Limited Ionic molecular conjugates of N-acylated derivatives of poly(2-amino-2-deoxy-D-glucose) and polypeptides
US5599535A (en) * 1995-06-07 1997-02-04 Regents Of The University Of California Methods for the cyto-protection of the trabecular meshwork
US5674888A (en) * 1995-06-07 1997-10-07 University Of California Method for the treatment of a trabecular meshwork whose cells are subject to inhibition of cell division
US6413536B1 (en) 1995-06-07 2002-07-02 Southern Biosystems, Inc. High viscosity liquid controlled delivery system and medical or surgical device
US5968542A (en) * 1995-06-07 1999-10-19 Southern Biosystems, Inc. High viscosity liquid controlled delivery system as a device
US5747058A (en) * 1995-06-07 1998-05-05 Southern Biosystems, Inc. High viscosity liquid controlled delivery system
US7833543B2 (en) * 1995-06-07 2010-11-16 Durect Corporation High viscosity liquid controlled delivery system and medical or surgical device
MX9700850A (es) 1995-06-09 1997-09-30 Euro Celtique Sa Formulaciones y metodos para proporcionar anestesia local prolongada.
US5955574A (en) 1995-07-13 1999-09-21 Societe De Conseils De Recherches Et D'applications Scientifiques, S.A. Analogs of parathyroid hormone
US5925351A (en) 1995-07-21 1999-07-20 Biogen, Inc. Soluble lymphotoxin-β receptors and anti-lymphotoxin receptor and ligand antibodies as therapeutic agents for the treatment of immunological disease
US6020473A (en) * 1995-08-25 2000-02-01 Genentech, Inc. Nucleic acids encoding variants of vascular endothelial cell growth factor
US7005505B1 (en) 1995-08-25 2006-02-28 Genentech, Inc. Variants of vascular endothelial cell growth factor
WO1997008220A1 (fr) * 1995-08-29 1997-03-06 Kyowa Hakko Kogyo Co., Ltd. Processus de production d'acide polyhydroxy carboxylique
WO1997007788A2 (fr) * 1995-08-31 1997-03-06 Alkermes Controlled Therapeutics, Inc. Composition se pretant a la liberation prolongee d'un agent
US5942253A (en) * 1995-10-12 1999-08-24 Immunex Corporation Prolonged release of GM-CSF
CA2192773C (fr) 1995-12-15 2008-09-23 Hiroaki Okada Obtention d'une preparation a liberation prolongee pour injection
US5980945A (en) * 1996-01-16 1999-11-09 Societe De Conseils De Recherches Et D'applications Scientifique S.A. Sustained release drug formulations
WO1997031049A1 (fr) * 1996-02-23 1997-08-28 Kyowa Hakko Kogyo Co., Ltd. Procede d'elaboration d'acide polyhydroxycarboxylique
US5747060A (en) * 1996-03-26 1998-05-05 Euro-Celtique, S.A. Prolonged local anesthesia with colchicine
IE960308A1 (en) * 1996-04-23 1997-11-05 Kinerton Ltd Sustained release ionic conjugate
WO1997040085A2 (fr) * 1996-04-23 1997-10-30 Kinerton Limited Polymeres polylactiques acides
US6100071A (en) 1996-05-07 2000-08-08 Genentech, Inc. Receptors as novel inhibitors of vascular endothelial growth factor activity and processes for their production
US5766877A (en) * 1996-05-10 1998-06-16 Amgen Inc. Genes encoding art, an agouti-related transcript
US5817343A (en) * 1996-05-14 1998-10-06 Alkermes, Inc. Method for fabricating polymer-based controlled-release devices
CA2260750C (fr) 1996-06-24 2004-11-09 Euro-Celtique, S.A. Methodes sures d'anesthesie locale
US6046187A (en) * 1996-09-16 2000-04-04 Children's Medical Center Corporation Formulations and methods for providing prolonged local anesthesia
US5952455A (en) * 1996-10-11 1999-09-14 Kyowa Hakko Kogyo Co., Ltd. Process for producing polyhydroxycarboxylic acid
PT939804E (pt) 1996-10-25 2005-11-30 Human Genome Sciences Inc Neutroquina alfa
PT839525E (pt) 1996-10-31 2004-10-29 Takeda Chemical Industries Ltd Preparacao de libertacao prolongada
US6156728A (en) 1996-11-01 2000-12-05 Genentech, Inc. Treatment of inner ear hair cells
US6593290B1 (en) 1996-11-01 2003-07-15 Genentech, Inc. Treatment of inner ear hair cells
US6919373B1 (en) 1996-11-12 2005-07-19 Alza Corporation Methods and devices for providing prolonged drug therapy
US7390891B1 (en) 1996-11-15 2008-06-24 Amgen Inc. Polynucleotides encoding a telomerase component TP2
US5919656A (en) * 1996-11-15 1999-07-06 Amgen Canada Inc. Genes encoding telomerase protein 1
US20020111603A1 (en) 1996-12-02 2002-08-15 Societe De Conseils De Recherches Et D'application Device for local administration of solid or semi-solid formulations and delayed-release formulations for proposal parental administration and preparation process
US6171788B1 (en) 1997-01-28 2001-01-09 The Regents Of The University Of California Methods for the diagnosis, prognosis and treatment of glaucoma and related disorders
US7138511B1 (en) 1997-01-28 2006-11-21 The Regents Of The University Of California Nucleic acids, kits and methods for the diagnosis, prognosis and treatment of glaucoma and related disorders
US6475724B1 (en) 1997-01-28 2002-11-05 The Regents Of The University Of California Nucleic acids, kits, and methods for the diagnosis, prognosis and treatment of glaucoma and related disorders
US7235524B2 (en) * 1997-01-31 2007-06-26 Applied Research System Ars Holding N.V. Medicaments for initiating ovulation
US5945126A (en) * 1997-02-13 1999-08-31 Oakwood Laboratories L.L.C. Continuous microsphere process
US6071982A (en) * 1997-04-18 2000-06-06 Cambridge Scientific, Inc. Bioerodible polymeric semi-interpenetrating network alloys for surgical plates and bone cements, and method for making same
US20060025328A1 (en) * 1997-05-28 2006-02-02 Burns Patrick J Compositions suitable for controlled release of the hormone GnRH and its analogs
ATE487737T1 (de) 1997-05-30 2010-11-15 Human Genome Sciences Inc 32 humane sekretierte proteine
US6867181B1 (en) 1997-06-02 2005-03-15 Societe De Conseils De Recherches Et D'applications Scientifiques, S.A.S. Ionic molecular conjugates of biodegradable polyesters and bioactive polypeptides
US6663899B2 (en) 1997-06-13 2003-12-16 Genentech, Inc. Controlled release microencapsulated NGF formulation
US6113947A (en) * 1997-06-13 2000-09-05 Genentech, Inc. Controlled release microencapsulated NGF formulation
EP1009390A4 (fr) * 1997-07-02 2004-05-06 Euro Celtique Sa Anesthesie a effet prolonge injectee dans les interlignes articulaires et corporelles
US6977074B2 (en) * 1997-07-10 2005-12-20 Mannkind Corporation Method of inducing a CTL response
US6994851B1 (en) 1997-07-10 2006-02-07 Mannkind Corporation Method of inducing a CTL response
US7923250B2 (en) 1997-07-30 2011-04-12 Warsaw Orthopedic, Inc. Methods of expressing LIM mineralization protein in non-osseous cells
ES2320603T3 (es) 1997-07-30 2009-05-25 Emory University Sistemas de expresion, vectores, adn, proteinas de mineralizacion osea novedosos.
US6342220B1 (en) 1997-08-25 2002-01-29 Genentech, Inc. Agonist antibodies
ES2333385T3 (es) 1997-09-17 2010-02-19 Human Genome Sciences, Inc. Proteina del tipo de interleuquina-17.
AU1384199A (en) 1997-11-07 1999-05-31 Chiron Corporation Method for producing igf-1 sustained-release formulations
US6372880B1 (en) 1997-12-25 2002-04-16 Mitsui Chemicals, Inc. Copolymer and process for preparing the same
US5906979A (en) * 1998-01-27 1999-05-25 Insmed Pharmaceuticals, Inc. Compositions and methods for treating metabolic diseases characterized by hyperandrogenism and/or anovulation and/or infertility
DE69916031T2 (de) * 1998-01-29 2005-02-17 Poly-Med Inc. Asorbierbare mikropartikel
DE69907870T2 (de) 1998-01-29 2004-03-04 Kinerton Ltd., Blanchardstown Verfahren zur herstellung von absorbierbaren mikropartikeln
NZ525914A (en) 1998-03-10 2004-03-26 Genentech Inc Novel polypeptides and nucleic acids encoding the same
US20030180368A1 (en) * 1998-03-14 2003-09-25 Cenes Drug Delivery Limited Production of microparticles
ATE405651T1 (de) 1998-03-17 2008-09-15 Genentech Inc Zu vegf und bmp1 homologe polypeptide
AU3072799A (en) 1998-03-19 1999-10-11 Human Genome Sciences, Inc. Cytokine receptor common gamma chain like
AR020650A1 (es) * 1998-08-10 2002-05-22 Poly Med Inc Polimeros fosforilados y conjugados de los mismos
US20030007991A1 (en) * 1998-09-25 2003-01-09 Masters David B. Devices including protein matrix materials and methods of making and using thereof
US6344541B1 (en) 1998-09-25 2002-02-05 Amgen Inc. DKR polypeptides
US7662409B2 (en) * 1998-09-25 2010-02-16 Gel-Del Technologies, Inc. Protein matrix materials, devices and methods of making and using thereof
CZ20011272A3 (cs) 1998-10-09 2001-09-12 Biogen, Inc. Použití činidla, které blokuje vazbu lymfotoxinu-beta na jeho receptor, pro výrobu protivirového léku
US6270802B1 (en) 1998-10-28 2001-08-07 Oakwood Laboratories L.L.C. Method and apparatus for formulating microspheres and microcapsules
US6565874B1 (en) * 1998-10-28 2003-05-20 Atrix Laboratories Polymeric delivery formulations of leuprolide with improved efficacy
US6143314A (en) * 1998-10-28 2000-11-07 Atrix Laboratories, Inc. Controlled release liquid delivery compositions with low initial drug burst
US6955822B1 (en) 1998-11-02 2005-10-18 Societe De Conseils De Recherches Et D'applications Scientifiques, Sas Of Paris Lactone bearing absorbable polymers
AUPP785098A0 (en) 1998-12-21 1999-01-21 Victor Chang Cardiac Research Institute, The Treatment of heart disease
US6365173B1 (en) 1999-01-14 2002-04-02 Efrat Biopolymers Ltd. Stereocomplex polymeric carriers for drug delivery
US6303749B1 (en) 1999-01-29 2001-10-16 Amgen Inc. Agouti and agouti-related peptide analogs
US6727224B1 (en) 1999-02-01 2004-04-27 Genetics Institute, Llc. Methods and compositions for healing and repair of articular cartilage
US7435796B1 (en) 1999-02-03 2008-10-14 Amgen Inc. Antibodies which bind B7RP1
AU773954B2 (en) 1999-02-03 2004-06-10 Amgen, Inc. Novel Polypeptides involved in immune response
US7708993B2 (en) 1999-02-03 2010-05-04 Amgen Inc. Polypeptides involved in immune response
US8624010B1 (en) 1999-02-03 2014-01-07 Steven K. Yoshinaga Nucleic acids encoding B7RP1
EP1156781B1 (fr) 1999-02-26 2005-06-08 Chiron Corporation Microemulsions avec des macromolecules adsorbees et microparticules
AU3501700A (en) 1999-02-26 2000-09-14 Human Genome Sciences, Inc. Human endokine alpha and methods of use
JP2002539172A (ja) 1999-03-17 2002-11-19 ノバルティス アクチエンゲゼルシャフト Ｔｇｆ−ベータを含む医薬組成物
WO2000058479A1 (fr) 1999-03-26 2000-10-05 Amgen Inc. Genes et polypeptides beta secretase
US6635249B1 (en) 1999-04-23 2003-10-21 Cenes Pharmaceuticals, Inc. Methods for treating congestive heart failure
US20030166561A1 (en) * 1999-06-18 2003-09-04 Cooper Garth J. S. Peptide
CN101633692A (zh) 1999-06-28 2010-01-27 杰南技术公司 利用二价金属离子制备Apo-2配体的方法
US7713739B1 (en) * 2000-11-17 2010-05-11 Novartis Vaccines And Diagnostics, Inc. Microparticle-based transfection and activation of dendritic cells
US7459540B1 (en) 1999-09-07 2008-12-02 Amgen Inc. Fibroblast growth factor-like polypeptides
US7408047B1 (en) 1999-09-07 2008-08-05 Amgen Inc. Fibroblast growth factor-like polypeptides
DK1223990T3 (da) 1999-10-15 2004-11-29 Inst Genetics Llc Formuleringer af hyaluronsyre til tilförsel af osteogene proteiner
US7078382B1 (en) 1999-11-02 2006-07-18 Genentech, Inc. Modulation of eNOS activity and therapeutic uses thereof
US6682754B2 (en) 1999-11-24 2004-01-27 Willmar Poultry Company, Inc. Ovo delivery of an immunogen containing implant
US6465425B1 (en) 2000-02-10 2002-10-15 Alkermes Controlled Therapeutics, Inc. Microencapsulation and sustained release of biologically active acid-stable or free sulfhydryl-containing proteins
US20030103978A1 (en) 2000-02-23 2003-06-05 Amgen Inc. Selective binding agents of osteoprotegerin binding protein
DE60120372T2 (de) * 2000-03-24 2007-07-05 Genentech Inc., San Francisco Verwendung von insulin zur behandlung von knorpelkrankheiten
US7514239B2 (en) 2000-03-28 2009-04-07 Amgen Inc. Nucleic acid molecules encoding beta-like glycoprotein hormone polypeptides and heterodimers thereof
EP2213743A1 (fr) 2000-04-12 2010-08-04 Human Genome Sciences, Inc. Protéines de fusion d'albumine
WO2001089500A2 (fr) * 2000-05-24 2001-11-29 Jordan Loyal Holtzman Agents et methodes d'augmentation des niveaux de chaperonines cerebrales
US20040033241A1 (en) * 2000-06-02 2004-02-19 Allergan, Inc. Controlled release botulinum toxin system
US6306423B1 (en) 2000-06-02 2001-10-23 Allergan Sales, Inc. Neurotoxin implant
US20040170665A1 (en) * 2000-06-02 2004-09-02 Allergan, Inc. Intravitreal botulinum toxin implant
EP2431054A3 (fr) 2000-06-15 2013-03-06 Human Genome Sciences, Inc. Facteur delta de nécrose de tumeur humaine et epsilon
EP2275549A1 (fr) 2000-06-23 2011-01-19 Genentech, Inc. Compositions et procédés pour le traitement et le diagnostic des troubles impliquant une angiogénèse
CA2648046A1 (fr) 2000-06-23 2002-01-03 Genentech, Inc. Compositions et procedes de diagnostic et de traitement de troubles dont l'angiogenese
ES2391124T3 (es) 2000-06-28 2012-11-21 Amgen Inc. Moléculas de receptor de linfopoyetina estromal tímica y usos de las mismas
CN1269870C (zh) * 2000-08-07 2006-08-16 和光纯药工业株式会社 乳酸聚合物及其制备方法
US6362308B1 (en) 2000-08-10 2002-03-26 Alkermes Controlled Therapeutics Inc. Ii Acid end group poly(d,l-lactide-co-glycolide) copolymers high glycolide content
US6565888B1 (en) 2000-08-23 2003-05-20 Alkermes Controlled Therapeutics, Inc. Methods and compositions for the targeted delivery of biologically active agents
AU8901901A (en) 2000-09-14 2002-03-26 Biogen Inc Tweak receptor agonists as anti-angiogenic agents background
AU2001296770A1 (en) * 2000-10-06 2002-04-15 Durect Corporation Devices and methods for management of inflammation
DE10055742B4 (de) 2000-11-10 2006-05-11 Schwarz Pharma Ag Neue Polyester, Verfahren zu ihrer Herstellung und aus den Polyestern hergestellte Depot-Arzneiformen
US8470359B2 (en) 2000-11-13 2013-06-25 Qlt Usa, Inc. Sustained release polymer
WO2004026111A2 (fr) 2000-11-16 2004-04-01 Microspherix Llc Grain ou fil de curietherapie flexible et/ou elastique
JP4236925B2 (ja) 2000-11-28 2009-03-11 アムジエン・インコーポレーテツド 免疫応答に関与する新規ポリペプチド
US6989247B2 (en) 2000-11-28 2006-01-24 Celltech R & D, Inc. Compositions and methods for diagnosing or treating psoriasis
AU2001298061A1 (en) 2000-12-13 2003-07-09 Purdue Research Foundation Microencapsulation of drugs by solvent exchange
US20030152637A1 (en) * 2001-01-25 2003-08-14 Mark Chasin Local anesthetic, and method of use
US7087726B2 (en) 2001-02-22 2006-08-08 Genentech, Inc. Anti-interferon-α antibodies
GB0111628D0 (en) 2001-05-11 2001-07-04 Scancell Ltd Binding member
US7226587B2 (en) 2001-06-01 2007-06-05 Wyeth Compositions and methods for systemic administration of sequences encoding bone morphogenetic proteins
AUPR546801A0 (en) 2001-06-05 2001-06-28 Commonwealth Scientific And Industrial Research Organisation Recombinant antibodies
TWI267378B (en) 2001-06-08 2006-12-01 Wyeth Corp Calcium phosphate delivery vehicles for osteoinductive proteins
WO2003000156A1 (fr) 2001-06-22 2003-01-03 Southern Biosystems, Inc. Implants coaxiaux a liberation prolongee d'ordre 0
EP2295081B1 (fr) 2001-06-26 2018-10-31 Amgen Inc. Anticorps OPGL
TWI332407B (en) 2001-06-29 2010-11-01 Takeda Chemical Industries Ltd Controlled release composition and method of producting the same
AU2002335657A1 (en) 2001-08-24 2003-03-10 Neuronz Biosciences, Inc. Neural regeneration peptide and methods for their use in treatment of brain damage
EP2311960A3 (fr) 2001-08-29 2011-06-01 Genentech, Inc. Acides nucléiques Bv8 et polypeptides avec activité mitogénique
AR036400A1 (es) * 2001-08-30 2004-09-08 Stem Cell Therapeutics Inc Regulacion combinada de la produccion de celulas nerviosas.
GB0122113D0 (en) * 2001-09-11 2001-10-31 Astrazeneca Ab Composition
ATE541921T1 (de) * 2001-09-14 2012-02-15 Stem Cell Therapeutics Inc Prolaktin-induzierte zunahme an neuronalen stammzellen und dessen therapeutische anwendung
US20030054551A1 (en) * 2001-09-18 2003-03-20 Stem Cell Therapeutics Inc. Effect of growth hormone and IGF-1 on neural stem cells
CN100350968C (zh) 2001-09-24 2007-11-28 皇家创新有限公司 饮食行为的改进
EP1501866A4 (fr) 2001-10-02 2006-02-08 Genentech Inc Variants de ligands apo-2 et leurs utilisations
AR045702A1 (es) 2001-10-03 2005-11-09 Chiron Corp Composiciones de adyuvantes.
US7521053B2 (en) 2001-10-11 2009-04-21 Amgen Inc. Angiopoietin-2 specific binding agents
US7138370B2 (en) 2001-10-11 2006-11-21 Amgen Inc. Specific binding agents of human angiopoietin-2
CA2462883A1 (fr) 2001-10-12 2003-04-17 Schering Corporation Utilisation d'anticorps bispecifiques pour reguler des reponses immunitaires
EP1450847B1 (fr) 2001-11-13 2010-09-29 Genentech, Inc. Compositions à base de APO2 ligand/TRAIL et leur utilisation
JP5170935B2 (ja) * 2001-11-14 2013-03-27 デュレクト コーポレーション 注入可能なデポー組成物
CU23043A1 (es) 2001-12-20 2005-05-20 Ct Ingenieria Genetica Biotech Composicion farmaceutica que contiene factor de crecimiento epidrmico (egf) para la prevencion de la amputacion de pie diabetico.
AU2002364586A1 (en) 2001-12-21 2003-07-30 Delta Biotechnology Limited Albumin fusion proteins
US8058233B2 (en) 2002-01-10 2011-11-15 Oregon Health And Science University Modification of feeding behavior using PYY and GLP-1
EP1474163A2 (fr) 2002-01-10 2004-11-10 Imperial College Innovations Limited Modification des habitudes alimentaires
US7662924B2 (en) 2002-02-22 2010-02-16 The Board Of Trustees Of The University Of Illinois Beta chain-associated regulator of apoptosis
AU2003225895A1 (en) * 2002-03-19 2003-10-08 Purdue Research Foundation Microencapsulation using ultrasonic atomizers
US7718776B2 (en) 2002-04-05 2010-05-18 Amgen Inc. Human anti-OPGL neutralizing antibodies as selective OPGL pathway inhibitors
WO2003087163A1 (fr) 2002-04-15 2003-10-23 Chugai Seiyaku Kabushiki Kaisha Procede d'elaboration d'une banque scdb
DE60327199D1 (de) 2002-04-26 2009-05-28 Chugai Pharmaceutical Co Ltd Verfahren zum screening auf agonistische antikörper
CA2483778A1 (fr) 2002-04-29 2003-11-13 Gel-Del Technologies, Inc. Systemes de fixation et de confinement structurels de matrices biologiques et procedes d'utilisation de ceux-ci
AU2002304965A1 (en) 2002-05-24 2003-12-12 Zensun (Shanghai) Sci-Tech.Ltd Neuregulin based methods and compositions for treating viral myocarditis and dilated cardiomyopathy
EP2305710A3 (fr) 2002-06-03 2013-05-29 Genentech, Inc. Bibliothèques de phages et anticorps synthétiques
DE10227232A1 (de) * 2002-06-18 2004-01-15 Aventis Pharma Deutschland Gmbh Saure Insulinzubereitungen mit verbesserter Stabilität
EP2500032A1 (fr) 2002-06-24 2012-09-19 Genentech, Inc. Variantes du ligand/Trail APO-2 et leurs utilisations
US20040001889A1 (en) 2002-06-25 2004-01-01 Guohua Chen Short duration depot formulations
US20050232995A1 (en) 2002-07-29 2005-10-20 Yam Nyomi V Methods and dosage forms for controlled delivery of paliperidone and risperidone
CA2492442A1 (fr) * 2002-07-31 2004-02-05 Stem Cell Therapeutics Inc. Procede d'amelioration de la proliferation, de la differentiation et de la survie de cellules souches neurales au moyen du polypeptide d'activation d'adenylate cyclase hypophysaire (pacap)
US20040142393A1 (en) * 2002-08-01 2004-07-22 Cooper Garth James Smith Methods of use of compounds with preptin function
US8075585B2 (en) * 2002-08-29 2011-12-13 Stryker Corporation Device and method for treatment of a vascular defect
KR101317045B1 (ko) 2002-09-06 2013-10-16 암젠 인코포레이티드 치료학적 인체 항-ｉｌ-1ｒ1 모노클로날 항체
WO2004034988A2 (fr) 2002-10-16 2004-04-29 Amgen Inc. Anticorps humains neutralisants anti-ifn-$g(g) utilises comme inhibiteurs selectifs des voies de ifn-$g(g)
US20040086532A1 (en) * 2002-11-05 2004-05-06 Allergan, Inc., Botulinum toxin formulations for oral administration
LT1576138T (lt) 2002-11-15 2017-06-26 Idenix Pharmaceuticals Llc 2`-šakoti nukleozidai derinyje su interferonu ir flaviviridae mutacija
US7285269B2 (en) 2002-12-02 2007-10-23 Amgen Fremont, Inc. Antibodies directed to tumor necrosis factor
ATE482695T1 (de) 2002-12-13 2010-10-15 Durect Corp Orale darreichungsform mit flüssigen hochviskosen trägersystemen
US7022481B2 (en) 2002-12-19 2006-04-04 Rosetta Inpharmatics Llc Methods of using glucan synthase pathway reporter genes to screen for antifungal compounds
WO2004060911A2 (fr) 2002-12-30 2004-07-22 Amgen Inc. Polytherapie a facteurs costimulants
GB0300571D0 (en) 2003-01-10 2003-02-12 Imp College Innovations Ltd Modification of feeding behaviour
EP1440992A1 (fr) * 2003-01-21 2004-07-28 Société de Conseils de Recherches et d'Applications Scientifiques ( S.C.R.A.S.) Système catalytique de (co)polymérisation du lactide et du glycolide
US7772188B2 (en) 2003-01-28 2010-08-10 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
EP1911763B1 (fr) 2003-01-28 2010-08-11 Ironwood Pharmaceuticals, Inc. Compositions pour le traitement de troubles gastrointestinaux
GB0304726D0 (en) * 2003-03-01 2003-04-02 Ardana Bioscience Ltd New Process
CA3007908A1 (fr) 2003-03-07 2005-04-14 Dsm Ip Assets B.V. Hydrolases, acides nucleiques les codant, et procedes de fabrication et d'utilisation correspondants
JP4912144B2 (ja) 2003-03-12 2012-04-11 ジェネンテック， インコーポレイテッド 造血促進のためのｂｖ８及び／又はｅｇ−ｖｅｇｆの使用
ATE510605T1 (de) 2003-03-14 2011-06-15 Univ Columbia Systeme und verfahren für auf blut basierende therapien mit einer membranlosen mikrofluid- austauschvorrichtung
US20060076295A1 (en) * 2004-03-15 2006-04-13 The Trustees Of Columbia University In The City Of New York Systems and methods of blood-based therapies having a microfluidic membraneless exchange device
WO2004084823A2 (fr) 2003-03-19 2004-10-07 Abgenix, Inc. Anticorps contre l'antigene de lymphocytes t, du domaine d'immunoglobuline et du domaine 1 de mucine (tim-1) et leurs utilisations
CA2519227C (fr) 2003-03-19 2013-12-03 Biogen Idec Ma Inc. Proteine de liaison de recepteur de nogo
CA2523266A1 (fr) * 2003-04-25 2004-11-11 Chiron Corporation Compositions de microparticules cationiques et d'adn de vhc e1, e2 et leurs procedes d'utilisation
ATE549028T1 (de) 2003-05-15 2012-03-15 Tufts College Stabile analoga von glp-1
US7375076B2 (en) 2003-05-20 2008-05-20 The Regents Of The University Of Michigan Methods of reducing vascular permeability in tissue by inhibition of tissue plasminogen activator (tPA) and tPA inhibitors useful therein
KR20130065723A (ko) 2003-06-27 2013-06-19 암젠 프레몬트 인코포레이티드 상피 성장 인자 수용체의 결실 돌연변이체 지향 항체 및 그 용도
ES2600554T3 (es) 2003-07-18 2017-02-09 Oakwood Laboratories L.L.C. Prevención de la reducción del peso molecular del polímero, de la formación de impurezas y de la gelificación en composiciones poliméricas
TWI476206B (zh) 2003-07-18 2015-03-11 Amgen Inc 對肝細胞生長因子具專一性之結合劑
US8541051B2 (en) * 2003-08-14 2013-09-24 Halliburton Energy Services, Inc. On-the fly coating of acid-releasing degradable material onto a particulate
US9149440B2 (en) * 2003-09-02 2015-10-06 University Of South Florida Nanoparticles for drug-delivery
GB0320806D0 (en) 2003-09-05 2003-10-08 Astrazeneca Ab Therapeutic treatment
EP2274978B1 (fr) 2003-09-12 2015-05-20 Tercica, Inc. Méthodes de traitement de la déficience du facteur de croissance de type insuline 1 (IGF-1)
JP5392981B2 (ja) 2003-09-12 2014-01-22 ワイス・エルエルシー 骨形成蛋白の送達のための注入可能なリン酸カルシウム固体ロッドおよびペースト
US7309232B2 (en) * 2003-10-10 2007-12-18 Dentigenix Inc. Methods for treating dental conditions using tissue scaffolds
WO2005035753A1 (fr) 2003-10-10 2005-04-21 Chugai Seiyaku Kabushiki Kaisha Anticorps a double specificite remplaçant une proteine fonctionnelle
US7783006B2 (en) * 2003-10-10 2010-08-24 Xoft, Inc. Radiation treatment using x-ray source
US20050080313A1 (en) * 2003-10-10 2005-04-14 Stewart Daren L. Applicator for radiation treatment of a cavity
AU2003271186A1 (en) 2003-10-14 2005-04-27 Chugai Seiyaku Kabushiki Kaisha Double specific antibodies substituting for functional protein
AU2004287431B2 (en) 2003-10-27 2010-03-11 Amgen Inc. Compositions and methods to modulate an immune response to an immunogenic therapeutic agent
CA2544678C (fr) 2003-11-05 2013-12-31 Sunesis Pharmaceuticals, Inc. Modulateurs de l'adhesion cellulaire
CN100534527C (zh) * 2003-12-30 2009-09-02 杜雷科特公司 用于控制释放优选为GnRH的活性剂的优选含有PEG和PLG的混合物的聚合植入物
AU2004313245B2 (en) * 2003-12-30 2011-04-14 Durect Corporation Polymeric implants, preferably containing a mixture of PEG and PLG, for controlled release of active agents, preferably a GNRH
AU2004313242A1 (en) * 2004-01-07 2005-07-28 Trimeris, Inc. HIV gp41 HR2-derived synthetic peptides, and their use in therapy to inhibit transmission of human immunodeficiency virus
BRPI0507169A (pt) 2004-02-02 2007-06-26 Ambrx Inc polipeptìdeos do hormÈnio de crescimento humano modificados e seu usos
US20070066525A1 (en) * 2004-02-04 2007-03-22 Lee John C Compositions and therapeutic methods using morphogenic proteins
CA2556266A1 (fr) 2004-02-13 2005-08-25 Stem Cell Therapeutics Corp. Utilisation de l'hormone de luteinisation (lh) et de la gonadotropine chorionique (hcg) pour la proliferation de cellules souches neuronales et la neurogenese
US7807176B2 (en) 2004-03-19 2010-10-05 Genomidea, Inc. Polypeptide promoting vascular endothelial cell growth
US20050260679A1 (en) 2004-03-19 2005-11-24 Sirid-Aimee Kellerman Reducing the risk of human anti-human antibodies through V gene manipulation
KR20060132006A (ko) 2004-03-23 2006-12-20 비오겐 아이덱 엠에이 아이엔씨. 수용체 커플링제 및 이의 치료적 용도
GB0410627D0 (en) 2004-05-12 2004-06-16 Scancell Ltd Specific binding members
EP1598428A1 (fr) 2004-05-18 2005-11-23 Georg Dewald Procédés et trousses pour la détection d'angioedema héréditaire type III
EP3461813A1 (fr) 2004-05-23 2019-04-03 Gerard M. Housey Modulateurs de theramuteine
CA2567405A1 (fr) 2004-05-25 2005-12-08 Stryker Corporation Utilisation des proteines morphogeniques pour traiter les anomalies des cartilages
US7632924B2 (en) 2004-06-18 2009-12-15 Ambrx, Inc. Antigen-binding polypeptides and their uses
ATE501252T1 (de) 2004-06-22 2011-03-15 Univ Illinois Verfahren zur inhibierung von tumorzellwachstum mit foxm1 sirns
US8486893B2 (en) 2004-06-24 2013-07-16 Biogen Idec Ma Inc. Treatment of conditions involving demyelination
WO2006004774A2 (fr) * 2004-06-28 2006-01-12 Stanford University Analogues de laulimalide en tant qu'agents therapeutiques
US20060004185A1 (en) * 2004-07-01 2006-01-05 Leese Richard A Peptide antibiotics and peptide intermediates for their prepartion
ME00226B (me) 2004-07-15 2011-02-10 Medarex Llc Humana anti-ngf neutrališuća antitijela kao selektivni inhibitori ngf signalne kaskade
WO2006091231A2 (fr) 2004-07-21 2006-08-31 Ambrx, Inc. Polypeptides biosynthetiques obtenus a partir d'acides amines codes par voie non naturelle
EP1789070B1 (fr) 2004-08-03 2012-10-24 Biogen Idec MA Inc. Influence du taj sur les fonctions neuronales
WO2006015373A2 (fr) 2004-08-04 2006-02-09 Amgen Inc Anticorps contre dkk-1
WO2006078320A2 (fr) * 2004-08-04 2006-07-27 Brookwood Pharmaceuticals, Inc. Procede de production de systemes d'administration, et systemes d'administration
DE602005013244D1 (de) 2004-08-12 2009-04-23 Quest Pharmaceutical Services Pharmazeutische zusammensetzungen für die kontroll
CN101106997A (zh) 2004-08-17 2008-01-16 约翰·霍普金斯大学 Pde5抑制剂组合物及治疗心脏病征候的方法
EP1802326A2 (fr) * 2004-09-09 2007-07-04 Stryker Corporation Methodes de traitement de tumeurs osseuses
AU2005287175B2 (en) 2004-09-17 2011-12-01 Durect Corporation Sustained local anesthetic composition containing preferably a sugar ester such as SAIB
JP2008515813A (ja) 2004-10-06 2008-05-15 アグリ−バイオテック ピーティーワイ リミテッド 抗体産生方法
FR2876379B1 (fr) * 2004-10-08 2008-09-05 Isochem Sa Procede de polymerisation des o-carboxy anhydrides
US8034345B2 (en) 2004-10-15 2011-10-11 Chugai Seiyaku Kabushiki Kaisha Anti-PCI antibody for regulating liver regeneration/repair
EP1824886B1 (fr) 2004-11-17 2010-12-22 Amgen Inc. Anticorps monoclonaux entierement humains diriges contre l'il-13
US7619007B2 (en) * 2004-11-23 2009-11-17 Adamas Pharmaceuticals, Inc. Method and composition for administering an NMDA receptor antagonist to a subject
GB0425854D0 (en) * 2004-11-25 2004-12-29 Astrazeneca Ab Therapeutic treatment
CA2592249C (fr) 2004-12-20 2014-07-29 Amgen Fremont Inc. Proteines de liaison specifiques de la matriptase humaine
ZA200705695B (en) 2004-12-21 2009-02-25 Astrazeneca Ab Antibodies directed to angiopoietin-2 and uses thereof
EP2399893B1 (fr) 2004-12-22 2018-08-15 Ambrx, Inc. Compositions contenant des acides aminés et des polypeptides non naturels, procédés les impliquant et leurs utilisations
BRPI0519430A2 (pt) 2004-12-22 2009-02-10 Ambrx Inc hormânio do crescimento humano modificado
EP1835885A1 (fr) * 2004-12-23 2007-09-26 Durect Corporation IMPLANTS POLYMÉRIQUES, CONTENANT DE PRÉFÉRENCE UN MÉLANGE DE PEG ET DE PLG, POUR UNE LIBÉRATION CONTRÔLÉE D'UNE GnRH
EP1838338A2 (fr) * 2004-12-29 2007-10-03 Mannkind Corporation Procedes permettant de declencher, maintenir et manipuler des modificateurs de reponse biologique a l'interieur d'organes lympoides
EP2361933A3 (fr) 2005-01-26 2012-05-02 Amgen Fremont Inc. Anticorps contre l'interleukine-1 bêta
ATE481096T1 (de) 2005-04-06 2010-10-15 Adamas Pharmaceuticals Inc Verfahren und zusammensetzungen zur behandlung von zns-erkrankungen
PT1876236E (pt) 2005-04-08 2014-10-22 Chugai Pharmaceutical Co Ltd Anticorpos para substituição da função do factor de coagulação sanguínea viii
US20090054320A1 (en) * 2005-04-20 2009-02-26 Protemix Discovery Limited Vesiculins
US20080095849A1 (en) * 2005-04-25 2008-04-24 Amgen Inc. Peptide sustained release compositions and uses thereof
ATE382337T1 (de) 2005-04-28 2008-01-15 Nipro Corp Bioabsorbierbare pharmazeutische zusammensetzung enthaltend einen plga-copolymer
EP1888052A2 (fr) 2005-05-12 2008-02-20 Wisconsin Alumni Research Foundation Blocage de pin1 pour empecher le production de cytokines par les cellules immunitaires activees
DK2444079T3 (en) 2005-05-17 2017-01-30 Sarcode Bioscience Inc Compositions and Methods for the Treatment of Eye Diseases
US8431110B2 (en) 2005-05-23 2013-04-30 Hmi Medical Innovations, Llc. Compounds and method of identifying, synthesizing, optimizing and profiling protein modulators
KR101367544B1 (ko) 2005-06-10 2014-02-26 추가이 세이야쿠 가부시키가이샤 메글루민을 함유하는 단백질 제제의 안정화제, 및 그의이용
JP5224580B2 (ja) 2005-06-10 2013-07-03 中外製薬株式会社 ｓｃ（Ｆｖ）２部位特異的変異体
BRPI0611901A2 (pt) 2005-06-14 2012-08-28 Amgen, Inc composição, liofilizado, kit, e, processo para preparar uma composição
HUE029021T2 (en) 2005-06-21 2017-02-28 Xoma (Us) Llc IL-1beta-binding antibodies and fragments thereof
HRP20131066T1 (hr) 2005-07-08 2013-12-06 Biogen Idec Ma Inc. Sp35 antitijela i njihova upotreba
EP2397498A3 (fr) 2005-07-18 2013-11-27 Amgen, Inc Anticorps humains à neutralisation anti-B7RP1
US20070027105A1 (en) 2005-07-26 2007-02-01 Alza Corporation Peroxide removal from drug delivery vehicle
US20100004156A1 (en) 2005-07-27 2010-01-07 Shalesh Kaushal Small Compounds That Correct Protein Misfolding and Uses Thereof
US8318668B2 (en) 2005-09-08 2012-11-27 Trustees Of Tufts College Stabilized GLP-1 analogs
WO2007036033A1 (fr) 2005-09-27 2007-04-05 Stem Cell Therapeutics Corp. Regulation par la prolactine de la proliferation des cellules precurseurs d'oligodendrocytes
CA2625447C (fr) 2005-09-29 2015-06-09 Societe De Conseils De Recherches Et D'applications Scientifiques S.A.S. Composition et procedes de stimulation de la motilite gastrointestinale
US8852638B2 (en) 2005-09-30 2014-10-07 Durect Corporation Sustained release small molecule drug formulation
WO2007142667A2 (fr) 2005-10-13 2007-12-13 Human Genome Sciences, Inc. Procédés et compositions destinées au traitement de patients atteints de maladies positives pour des auto-anticorps
WO2007043641A1 (fr) 2005-10-14 2007-04-19 Fukuoka University Inhibiteur de dysfonctionnement d'îlots transplantés dans un transplant d'îlots
AR058135A1 (es) 2005-10-21 2008-01-23 Chugai Pharmaceutical Co Ltd Agentes para el tratamiento de cardiopatias
WO2007056161A1 (fr) 2005-11-04 2007-05-18 Biogen Idec Ma Inc. Procedes favorisant la croissance des neurites et la survie des neurones dopaminergiques
US20070106271A1 (en) * 2005-11-09 2007-05-10 Searete Llc, A Limited Liability Corporation Remote control of substance delivery system
EP1957115B8 (fr) 2005-11-10 2014-03-05 Celldex Therapeutics, Inc. Methode de traitement du cancer de l'ovaire et du rein utilisant des anticorps diriges contre l'antigene a domaine 1 de mucine et a domaine immunoglobuline des lymphocytes t (tim-1)
TW200736277A (en) 2005-11-14 2007-10-01 Amgen Inc RANKL antibody-PTH/PTHrP chimeric molecules
EP1964574B1 (fr) 2005-11-14 2016-09-07 Cellmid Limited Procede de traitement ou de prevention d une maladie associee a un trouble fonctionnel des lymphocytes t regulateurs
AR057582A1 (es) 2005-11-15 2007-12-05 Nat Hospital Organization Agentes para suprimir la induccion de linfocitos t citotoxicos
DK2339014T3 (en) 2005-11-16 2015-07-20 Ambrx Inc Methods and compositions comprising non-natural amino acids
TW200803894A (en) 2005-11-25 2008-01-16 Univ Keio Prostate cancer therapeutic agents
EP1962901A2 (fr) 2005-12-01 2008-09-03 The Provost, Fellows And Scholars Of The College Of The Holy And Undivided Trinity Of Queen Elizabeth Near Dublin Compositions et methodes relatives au traitement du cancer et de maladies infectieuses
JP5312039B2 (ja) 2005-12-02 2013-10-09 バイオジェン・アイデック・エムエイ・インコーポレイテッド 脱髄の関与する状態の処置
US20070213264A1 (en) 2005-12-02 2007-09-13 Mingdong Zhou Neuregulin variants and methods of screening and using thereof
WO2008024128A2 (fr) 2005-12-05 2008-02-28 Simon Delagrave Domaines pdz variants de boucle en tant que produits biothérapeutiques, produits diagnostiques et réactifs de recherche
AU2006322887A1 (en) 2005-12-05 2007-06-14 The Provost, Fellows And Scholars Of The College Of The Holy And Undivided Trinity Of Queen Elizabeth Near Dublin Compositions and methods for modulating an immune response
DK1979001T3 (da) 2005-12-13 2012-07-16 Medimmune Ltd Bindingsproteiner, der er specifikke for insulinlignende vækstfaktorer og anvendelser deraf
AU2005339101B2 (en) 2005-12-14 2013-01-10 Herantis Pharma Plc. Novel neurotrophic factor protein and uses thereof
EP1962903B1 (fr) 2005-12-15 2013-03-13 MedImmune Limited Combinaison d'un antagoniste de l'angiopoietine 2 et d'un antagoniste du vegf-a et/ou du kdr et/ou du fltl pour le traitement du cancer
ES2530526T3 (es) 2005-12-30 2015-03-03 Zensun Shanghai Science And Technology Ltd Liberación extendida de neurregulina para mejorar la función cardíaca
US20070154546A1 (en) * 2005-12-30 2007-07-05 Zhang Jack Y Sustained release pharmaceutical compositions
KR20080094910A (ko) 2006-01-17 2008-10-27 디나벡크 가부시키가이샤 신규 단백질 발현계
WO2007084460A2 (fr) * 2006-01-18 2007-07-26 Qps, Llc Compositions pharmaceutiques a stabilite amelioree
AU2007208678B2 (en) 2006-01-27 2013-01-10 Chugai Seiyaku Kabushiki Kaisha Therapeutic agents for diseases involving choroidal neovascularization
PT1981902E (pt) 2006-01-27 2015-11-02 Biogen Ma Inc Antagonistas dos recetores nogo
US7756524B1 (en) 2006-01-31 2010-07-13 Nextel Communications Inc. System and method for partially count-based allocation of vocoder resources
CU23388B6 (es) 2006-01-31 2009-07-16 Ct Ingenieria Genetica Biotech Composición farmacéutica de microesferas para prevenir la amputación del pie diabético
US20070178138A1 (en) * 2006-02-01 2007-08-02 Allergan, Inc. Biodegradable non-opthalmic implants and related methods
TWI341844B (en) 2006-02-02 2011-05-11 Trimeris Inc Hiv fusion inhibitor peptides with improved biological properties
EP1987142A4 (fr) 2006-02-02 2009-07-15 Verenium Corp Estérases, acides nucléiques apparentés et procédés associés
WO2007106987A1 (fr) * 2006-03-17 2007-09-27 Stem Cell Therapeutics Corp. Régimes de dosage continu pour agents de prolifération des cellules souches nerveuses et agents de différentiation desdites cellules
EP1837014A1 (fr) * 2006-03-21 2007-09-26 Hexal Ag Implants sous-cutanés contenant un polymère de polylactide résistant à la dégradation et un analogue de la LH-RH
JP5754875B2 (ja) 2006-04-07 2015-07-29 国立大学法人大阪大学 筋再生促進剤
TW200813091A (en) 2006-04-10 2008-03-16 Amgen Fremont Inc Targeted binding agents directed to uPAR and uses thereof
PL2018184T3 (pl) 2006-05-17 2013-12-31 The Ludwig Institute For Cancer Res Przeciwciało Anty-VEGF-B do stosowania w leczeniu lub profilaktyce cukrzycy typu II lub zespołu metabolicznego
CA2652549A1 (fr) 2006-05-17 2007-12-13 Stryker Corporation Procede pour traiter des defauts cartilagineux a l'aide d'uncomplexe de proteine morphogenique soluble
US7403325B2 (en) * 2006-05-19 2008-07-22 Xerox Corporation Electrophoretic display device
CN101534917A (zh) 2006-05-22 2009-09-16 纽约市哥伦比亚大学理事会 采用萃取流体排出流过滤的微流无膜交换系统和方法
US20100022457A1 (en) 2006-05-26 2010-01-28 Bristol-Myers Squibb Company Sustained release glp-1 receptor modulators
US8124743B2 (en) 2006-06-01 2012-02-28 President And Fellows Of Harvard College Purification of a bivalently active antibody using a non-chromatographic method
ES2429407T3 (es) 2006-06-08 2013-11-14 Chugai Seiyaku Kabushiki Kaisha Agente preventivo o remedio para enfermedades inflamatorias
GB0611405D0 (en) 2006-06-09 2006-07-19 Univ Belfast FKBP-L: A novel inhibitor of angiogenesis
US20100150927A1 (en) 2006-07-13 2010-06-17 Chugai Seiyaku Kabushiki Kaisha Cell death inducer
WO2008008827A2 (fr) * 2006-07-13 2008-01-17 Medtronic, Inc. Procédés et formulations pour la délivrance locale optimale de thérapie cellulaire via des procédures à invasion minimale
WO2008010556A1 (fr) 2006-07-21 2008-01-24 Chugai Seiyaku Kabushiki Kaisha Médicament agissant contre une maladie rénale
CA2658786A1 (fr) 2006-07-28 2008-01-31 Children's Memorial Hospital Procedes d'inhibition de l'agressivite des cellules tumorales a l'aide du microenvironnement des cellules souches embryonnaires humaines
CL2007002225A1 (es) 2006-08-03 2008-04-18 Astrazeneca Ab Agente de union especifico para un receptor del factor de crecimiento derivado de plaquetas (pdgfr-alfa); molecula de acido nucleico que lo codifica; vector y celula huesped que la comprenden; conjugado que comprende al agente; y uso del agente de un
US9505823B2 (en) 2006-08-07 2016-11-29 TEV A Biopharmaceuticals USA, Inc. Albumin-insulin fusion proteins
CN106008699A (zh) 2006-09-08 2016-10-12 Ambrx公司 经修饰的人类血浆多肽或Fc骨架和其用途
US7767206B2 (en) 2006-10-02 2010-08-03 Amgen Inc. Neutralizing determinants of IL-17 Receptor A and antibodies that bind thereto
CN101600450A (zh) 2006-10-20 2009-12-09 比奥根艾迪克Ma公司 利用可溶性淋巴毒素β受体的脱髓鞘病的治疗
US8338376B2 (en) 2006-10-20 2012-12-25 Biogen Idec Ma Inc. Compositions comprising variant LT-B-R-IG fusion proteins
US8337883B2 (en) 2006-11-03 2012-12-25 Durect Corporation Transdermal delivery systems
ES2437110T3 (es) 2006-11-14 2014-01-08 Genentech, Inc. Moduladores de la regeneración neuronal
WO2008073300A2 (fr) 2006-12-08 2008-06-19 Lexicon Pharmaceuticals, Inc. Anticorps monoclonaux dirigés contre angptl3
TWI428346B (zh) 2006-12-13 2014-03-01 Imp Innovations Ltd 新穎化合物及其等對進食行為影響
MX2009006653A (es) 2006-12-18 2009-07-02 Takeda Pharmaceutical Composicion de liberacion prolongada y metodo para producirla.
EP3124045A3 (fr) 2006-12-20 2017-05-03 Xoma (Us) Llc Traitement de maladies apparentées il-1 beta
US8128926B2 (en) 2007-01-09 2012-03-06 Biogen Idec Ma Inc. Sp35 antibodies and uses thereof
BRPI0806340B8 (pt) 2007-01-09 2021-05-25 Biogen Idec Inc anticorpo isolado que se liga especificamente a sp35, seu uso e composição farmacêutica
TWI438208B (zh) 2007-01-23 2014-05-21 中外製藥股份有限公司 抑制慢性排斥反應之藥劑
SG178744A1 (en) 2007-02-02 2012-03-29 Biogen Idec Inc Use of semaphorin 6a for promoting myelination and oligodendrocyte differentiation
US7947646B2 (en) 2007-03-06 2011-05-24 Amgen Inc. Variant activin receptor polypeptides
US8501678B2 (en) 2007-03-06 2013-08-06 Atara Biotherapeutics, Inc. Variant activin receptor polypeptides and uses thereof
CL2008000719A1 (es) 2007-03-12 2008-09-05 Univ Tokushima Chugai Seiyaku Agente terapeutico para cancer resistente a agentes quimioterapeuticos que comprende un anticuerpo que reconoce hla de clase i como ingrediente activo; composicion farmaceutica que comprende dicho anticuerpo; y metodo para tratar cancer resistente a
CN107501407B (zh) 2007-03-30 2022-03-18 Ambrx公司 经修饰fgf-21多肽和其用途
CA2682848A1 (fr) * 2007-04-03 2008-10-16 Trimeris, Inc. Nouvelles formulations destinees a l'application de therapies peptidiques antivirales
US20100290982A1 (en) * 2007-04-13 2010-11-18 University Of North Texas Health Science Center At Fort Worth Solid in oil/water emulsion-diffusion-evaporation formulation for preparing curcumin-loaded plga nanoparticles
MX2009010907A (es) 2007-04-13 2010-03-17 Univ North Texas Formulacion del agente activo cargado en nanoparticulas de plga activadas para nano-terapeuticos direccionados para el cancer.
WO2008140026A1 (fr) 2007-05-11 2008-11-20 Bizen Chemical Co., Ltd. Antagoniste inédit du récepteur des leucotriènes
EP2167039B1 (fr) * 2007-05-18 2016-09-28 Durect Corporation Formulations à dépôt amélioré
ES2562878T3 (es) 2007-05-25 2016-03-08 Indivior Uk Limited Formulaciones de liberación sostenida de compuestos de risperidona
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
MX354786B (es) 2007-06-04 2018-03-21 Synergy Pharmaceuticals Inc Agonistas de guanilato ciclasa utiles para el tratamiento de trastornos gastrointestinales, inflamacion, cancer y otros trastornos.
GB0710976D0 (en) 2007-06-07 2007-07-18 Bioalvo Am Screening method
NZ595526A (en) * 2007-06-14 2013-03-28 Biogen Idec Inc Pharmaceutical composition comprising a vla-4 binding antibody, a phosphate buffer and a surfactant
WO2011084685A2 (fr) 2009-12-17 2011-07-14 Children's Medical Center Corporation Peptides dérivés de saposine a et utilisations de ceux-ci
CA2692171C (fr) 2007-06-22 2019-10-22 Randolph Watnick Procedes et utilisations de prosaposine
WO2009002193A1 (fr) 2007-06-27 2008-12-31 Auckland Uniservices Limited Polypeptides et polynucléotides pour l'artémine et les ligands apparentés, et leurs procédés d'utilisation
EP2174667B1 (fr) 2007-07-26 2017-01-04 Osaka University Agent pour le traitement de l'ophtalmie contenant un inhibiteur du récepteur de l'interleukine 6 en tant qu'ingrédient actif
DE102007036101A1 (de) * 2007-08-01 2009-02-05 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue glycolidreiche Copolymere
TW200916113A (en) 2007-08-08 2009-04-16 Sod Conseils Rech Applic Method for inhibiting inflammation and pro-inflammatory cytokine/chemokine expression using a ghrelin analogue
PL2188313T3 (pl) 2007-08-21 2018-04-30 Amgen, Inc. Białka wiążące ludzki antygen c-fms
EP2615114B1 (fr) 2007-08-23 2022-04-06 Amgen Inc. Protéines de liaison à un antigène pour proprotéine convertase subtilisine kexine de type 9 (PCSK9)
JOP20080381B1 (ar) 2007-08-23 2023-03-28 Amgen Inc بروتينات مرتبطة بمولدات مضادات تتفاعل مع بروبروتين كونفيرتاز سيتيليزين ككسين من النوع 9 (pcsk9)
US7982016B2 (en) 2007-09-10 2011-07-19 Amgen Inc. Antigen binding proteins capable of binding thymic stromal lymphopoietin
US20090156488A1 (en) 2007-09-12 2009-06-18 Zensun (Shanghai) Science & Technology Limited Use of neuregulin for organ preservation
TW200918553A (en) 2007-09-18 2009-05-01 Amgen Inc Human GM-CSF antigen binding proteins
EP2040075A1 (fr) 2007-09-24 2009-03-25 Julius-Maximilians-Universität Würzburg Composés et marqueurs pour la diffusion Raman de surface améliorée
CN101874038A (zh) * 2007-09-25 2010-10-27 特里梅里斯公司 治疗性抗-hiv肽的合成方法
EP2497783A3 (fr) 2007-09-26 2013-04-17 U3 Pharma GmbH Protéines de liaison avec l'antigène du facteur de croissance de type facteur de croissance épidermique se liant à l'héparine
RU2490025C2 (ru) 2007-10-02 2013-08-20 Чугаи Сейяку Кабусики Кайся Терапевтические средства, используемые против реакции трансплантат против хозяина, содержащие в качестве активного ингредиента ингибитор рецептора интерлейкина-6
JP2010540618A (ja) * 2007-10-02 2010-12-24 アリエル−ユニバーシティー リサーチ アンド デベロップメント カンパニー リミテッド 幼児の成長および発達を増大するための内在性カンナビノイド
US20090123508A1 (en) * 2007-10-04 2009-05-14 Boston Scientific Scimed, Inc. Implantable Drug Depot for Intrathecal Drug Delivery System for Pain Management
ES2830024T3 (es) 2007-10-19 2021-06-02 Novartis Ag Composiciones y métodos para el tratamiento del edema macular
EP2219620B1 (fr) * 2007-11-13 2017-07-19 Surmodics, Inc. Terpolymères visqueux en tant que plateforme de délivrance de médicaments
EP2207568B1 (fr) 2007-11-16 2017-05-31 The Rockefeller University Anticorps spécifiques de la forme de protofibrille de protéine bêta-amyloïde
MX2010005317A (es) 2007-11-20 2010-06-02 Ambrx Inc Polipeptidos de insulina modificados y sus usos.
TW201634479A (zh) 2007-12-05 2016-10-01 中外製藥股份有限公司 抗ｎｒ１０抗體及其應用
CA2708065C (fr) 2007-12-05 2015-02-24 Chugai Seiyaku Kabushiki Kaisha Agent therapeutique contre le prurit
EP2219622A1 (fr) 2007-12-06 2010-08-25 Durect Corporation Procédés utiles dans le traitement de la douleur, d'états rhumatismaux ou d'inflammations associées à un état chronique
EP2241333A1 (fr) 2007-12-12 2010-10-20 National Cancer Center Agent thérapeutique pour une leucémie mll et une leucémie moz dont la cible moléculaire est le récepteur m-csf, et son utilisation
SI2391650T1 (sl) 2007-12-20 2015-03-31 Xoma (Us) Llc Postopki za zdravljenje protina
US20090181068A1 (en) * 2008-01-14 2009-07-16 Dunn Richard L Low Viscosity Liquid Polymeric Delivery System
EP2249899A4 (fr) * 2008-02-04 2011-05-11 Univ Columbia Dispositifs de séparation de fluide, systèmes et procédés
MX344166B (es) 2008-02-08 2016-12-07 Ambrx Inc Leptina-polipeptidos modificados y sus usos.
JO2913B1 (en) 2008-02-20 2015-09-15 امجين إنك, Antibodies directed towards angiopoietin-1 and angiopoietin-2 proteins and their uses
EP2251006B1 (fr) * 2008-02-22 2017-07-19 Toray Industries, Inc. Microparticules et leurs compositions pharmaceutiques
WO2009139817A2 (fr) 2008-04-15 2009-11-19 Sarcode Corporation Produit pharmaceutique cristallin et ses procédés de préparation et d'utilisation
FI20080326A0 (fi) 2008-04-30 2008-04-30 Licentia Oy Neurotroofinen tekijä MANF ja sen käytöt
US8034770B2 (en) 2008-06-04 2011-10-11 Amgen Inc. FGF21 polypeptides comprising two or more mutations
ES2522968T3 (es) 2008-06-04 2014-11-19 Synergy Pharmaceuticals Inc. Agonistas de guanilato ciclasa útiles para el tratamiento de trastornos gastrointestinales, inflamación, cáncer y otros trastornos
CA2728243C (fr) 2008-06-05 2020-03-10 Chugai Seiyaku Kabushiki Kaisha Inhibiteur de neuro-invasion
EP2687513B1 (fr) 2008-06-09 2020-12-02 Ludwig-Maximilians-Universität München Médicaments pour l'inhibition de l'agrégation des protéines impliquées dans des maladies associées à l'agrégation des protéines et/ou des maladies neurodégénératives
EP2307456B1 (fr) 2008-06-27 2014-10-15 Amgen Inc. Inhibition de l ang-2 pour traiter la sclérose en plaques
CA2729961C (fr) 2008-07-09 2018-05-01 Biogen Idec Ma Inc. Anticorps anti-lingo, li113, li62 variant co2
AU2009270833B2 (en) 2008-07-16 2015-02-19 Bausch Health Ireland Limited Agonists of guanylate cyclase useful for the treatment of gastrointestinal, inflammation, cancer and other disorders
CN102159230A (zh) 2008-07-23 2011-08-17 Ambrx公司 经修饰的牛g-csf多肽和其用途
CN103751842A (zh) 2008-07-30 2014-04-30 米辛瑟斯有限公司 衍生自前胃胞外基质的组织支架
US8198062B2 (en) 2008-08-29 2012-06-12 Dsm Ip Assets B.V. Hydrolases, nucleic acids encoding them and methods for making and using them
US8357503B2 (en) 2008-08-29 2013-01-22 Bunge Oils, Inc. Hydrolases, nucleic acids encoding them and methods for making and using them
US8153391B2 (en) 2008-08-29 2012-04-10 Bunge Oils, Inc. Hydrolases, nucleic acids encoding them and methods for making and using them
SG193209A1 (en) 2008-09-10 2013-09-30 Genentech Inc Methods for inhibiting ocular angiogenesis
AU2009294415B2 (en) 2008-09-19 2015-09-24 Medimmune Llc Antibodies directed to DLL4 and uses thereof
AU2009296267B2 (en) 2008-09-26 2013-10-31 Ambrx, Inc. Non-natural amino acid replication-dependent microorganisms and vaccines
BR122012024318A2 (pt) 2008-09-26 2019-07-30 Ambrx, Inc. Polipeptídeos modificados de eritropoetina animal e seus usos
CA2739615C (fr) 2008-10-10 2017-12-05 Amgen Inc. Mutants fgf21 et leurs utilisations
JP2012504969A (ja) 2008-10-10 2012-03-01 アナフォア インコーポレイテッド Ｔｒａｉｌ−ｒ１及びｔｒａｉｌ−ｒ２に結合するポリペプチド
JP5851838B2 (ja) 2008-10-22 2016-02-03 ジェネンテック， インコーポレイテッド 軸索変性の調節
CA2738243C (fr) 2008-10-29 2020-09-29 Wyeth Llc Formulations de molecules de liaison d'antigene monodomaines
US20100260844A1 (en) 2008-11-03 2010-10-14 Scicinski Jan J Oral pharmaceutical dosage forms
CA2744120A1 (fr) 2008-11-17 2010-05-20 The Provost, Fellows, Foundation Scholars, And The Other Members Of Boar D, Of The College Of The Holy And Undivided Trinity Of Queen Elizabeth, Peptide de proteine a46 de virus de la vaccine et utilisation de celui-ci
JP5611222B2 (ja) 2008-11-26 2014-10-22 アムジエン・インコーポレーテツド アクチビンｉｉｂ受容体ポリペプチドの変異体及びその使用
WO2010070136A2 (fr) 2008-12-19 2010-06-24 Centre de Recherche Public de la Santé Nouveaux allergènes de caviidae et leurs utilisations
EP2367564A1 (fr) 2008-12-22 2011-09-28 Universität Regensburg Utilisation de la protéine norrin dans le traitement de maladies associées à une augmentation de l'activité de tgf-bêta
CA2748158A1 (fr) 2008-12-23 2010-07-01 Astrazeneca Ab Agents de liaison cibles diriges contre .alpha.5.beta.1 et leurs applications
US20100168807A1 (en) * 2008-12-23 2010-07-01 Burton Kevin W Bioactive terpolymer compositions and methods of making and using same
US8974808B2 (en) * 2008-12-23 2015-03-10 Surmodics, Inc. Elastic implantable composites and implants comprising same
US20100158978A1 (en) * 2008-12-23 2010-06-24 Peter Markland Bioactive spray coating compositions and methods of making and uses thereof
TW201035111A (en) 2008-12-23 2010-10-01 Biosource Pharm Inc Antibiotic compositions for the treatment of gram negative infections
US9415197B2 (en) 2008-12-23 2016-08-16 Surmodics, Inc. Implantable suction cup composites and implants comprising same
JO3382B1 (ar) 2008-12-23 2019-03-13 Amgen Inc أجسام مضادة ترتبط مع مستقبل cgrp بشري
US8951546B2 (en) 2008-12-23 2015-02-10 Surmodics Pharmaceuticals, Inc. Flexible implantable composites and implants comprising same
EP2390261A4 (fr) 2009-01-20 2012-11-14 Hanall Biopharma Co Ltd Fragment polypeptidique de thrombopoïétine humaine modifié et son procédé de fabrication
WO2010085608A1 (fr) * 2009-01-23 2010-07-29 Surmodics Pharmaceuticals, Inc. Mélanges de polymères comprenant des polymères ayant différentes unités non répétitives et leurs procédés de fabrication et d'utilisation
CA2750003A1 (fr) * 2009-01-23 2010-07-29 Surmodics Pharmaceuticals, Inc. Systeme a liberation controlee de melange polymeres
WO2010093993A2 (fr) 2009-02-12 2010-08-19 Human Genome Sciences, Inc. Utilisation d'antagonistes de la protéine stimulant les lymphocytes b afin de favoriser la tolérance aux greffes
EP2396344A2 (fr) 2009-02-13 2011-12-21 Novartis AG Molécule d'acide nucléique d'un agrégat biosynthétique codant pour des synthases peptidiques non ribosomales et leurs utilisations
TW201031436A (en) * 2009-02-16 2010-09-01 Univ Nat Taiwan Pharmaceutical composition for inhalation delivery and fabrication method thereof
WO2010094624A1 (fr) 2009-02-18 2010-08-26 Bayer Schering Pharma Aktiengesellschaft Particules comprenant de la drospirénone encapsulée dans un polymère
JP2010210772A (ja) 2009-03-13 2010-09-24 Dainippon Screen Mfg Co Ltd 液晶表示装置の製造方法
WO2010129503A1 (fr) 2009-05-05 2010-11-11 Amgen Inc. Mutants de fgf21 et leurs utilisations
WO2010129600A2 (fr) 2009-05-05 2010-11-11 Amgen Inc. Mutants de fgf21 et leurs utilisations
EP2260857A1 (fr) 2009-06-11 2010-12-15 Alfact Innovation Nouvelles applications de HIP/PAP ou dérivés associés
WO2010144797A2 (fr) 2009-06-12 2010-12-16 Vaccine Technologies, Incorporated Vaccins contre la grippe avec immunogénicité accrue et leurs utilisations
IN2012DN00352A (fr) 2009-06-16 2015-08-21 Bikam Pharmaceuticals Inc
MX2011013903A (es) 2009-06-17 2012-05-08 Amgen Inc Polipeptidos quimericos y usos de los mismos.
WO2011010132A1 (fr) 2009-07-21 2011-01-27 Astrazeneca Ab Composé 600
WO2011010131A1 (fr) 2009-07-21 2011-01-27 Astrazeneca Ab Compositions comprenant un oxoisoquinoléin-méthylbenzamide et un polymère
WO2011013786A1 (fr) 2009-07-31 2011-02-03 Maeda Shin Inhibiteur de métastases cancéreuses
TW201118166A (en) 2009-09-24 2011-06-01 Chugai Pharmaceutical Co Ltd HLA class I-recognizing antibodies
EP2305285A1 (fr) 2009-09-29 2011-04-06 Julius-Maximilians-Universität Würzburg Supports et procédés pour traiter les conditions ischémiques
EP2305810A1 (fr) 2009-10-02 2011-04-06 Technische Universität München miARN pour le traitement de la fibrose
EP2308478A1 (fr) 2009-10-06 2011-04-13 Abbott GmbH & Co. KG Système de libération prolongée d'agents bloquants des canaux calciques
TW201117824A (en) 2009-10-12 2011-06-01 Amgen Inc Use of IL-17 receptor a antigen binding proteins
CN102711772A (zh) 2009-10-16 2012-10-03 奥克兰联合服务有限公司 Artemin拮抗剂的抗肿瘤用途
EP2492281B1 (fr) 2009-10-19 2018-04-11 HanAll Biopharma Co., Ltd. Polypeptide modifié du récepteur 1 du facteur humain de nécrose tumorale ou son fragment, et méthode de préparation associée
WO2011050175A1 (fr) 2009-10-21 2011-04-28 Sarcode Corporation Agent pharmaceutique cristallin et procédés de préparation et utilisation de celui-ci
EP3011970A3 (fr) 2009-10-22 2016-06-08 F. Hoffmann-La Roche AG Modulation de la dégénérescence axonale
US8729058B2 (en) 2009-10-27 2014-05-20 Michael Zasloff Methods and compositions for treating and preventing viral infections
MX341084B (es) 2009-11-02 2016-08-05 Univ Washington Composiciones de nucleasas terapéuticas y métodos.
EP2498803A4 (fr) 2009-11-13 2013-05-15 Puget Sound Blood Ct Variants d'épitopes des lymphocytes t du facteur viii à immunogénicité réduite
PL2504364T3 (pl) 2009-11-24 2017-12-29 Medimmune Limited Ukierunkowane środki wiążące przeciwko B7-H1
WO2011066260A2 (fr) 2009-11-25 2011-06-03 Michael Zasloff Formulations comprenant des aminostérols
US8491927B2 (en) 2009-12-02 2013-07-23 Nimble Epitech, Llc Pharmaceutical composition containing a hypomethylating agent and a histone deacetylase inhibitor
CA2994873A1 (fr) 2009-12-02 2011-06-09 Adamas Pharma, Llc Compositions d'amantadine et procedes d'utilisation associes
UA109888C2 (uk) 2009-12-07 2015-10-26 ІЗОЛЬОВАНЕ АНТИТІЛО АБО ЙОГО ФРАГМЕНТ, ЩО ЗВ'ЯЗУЄТЬСЯ З β-КЛОТО, РЕЦЕПТОРАМИ FGF І ЇХНІМИ КОМПЛЕКСАМИ
BR112012015597A2 (pt) 2009-12-21 2017-01-31 Ambrx Inc peptídeos de somatotropina suínos modificados e seus usos
MX349301B (es) 2009-12-21 2017-07-21 Ambrx Inc Polipéptidos de somatotropina bovina modificados y sus usos.
BR112012017535A2 (pt) 2010-01-15 2019-09-24 Of Medicine And Dentistry Of New Jersey University uso de compostos de vanádio para cicatrização de osso
US20130053438A1 (en) 2010-01-19 2013-02-28 Universitat Innsbruck Pharmaceutical compositions comprising lignans and their derivatives for the medical management of angiogenesis and hypovascularity
WO2011094430A2 (fr) 2010-01-27 2011-08-04 Children's Medical Center Corporation Fragments proangiogènes de prominine 1 et utilisations de ceux-ci
JP2013517782A (ja) 2010-01-28 2013-05-20 ノヴォ・ノルディスク・ヘルス・ケア・アーゲー 因子ｖｉｉ融合ポリペプチド
WO2011099007A1 (fr) 2010-02-10 2011-08-18 Nayacure Therapeutics Ltd. Compositions pharmaceutiques et procédés de traitement et de prévention du cancer
GB201003559D0 (en) 2010-03-03 2010-04-21 Proteo Biotech Ag Novel use of elafin
JP2013525271A (ja) 2010-03-12 2013-06-20 チルドレンズ メディカル センター コーポレーション 免疫原およびそのスクリーニング方法
CN103038255A (zh) 2010-03-26 2013-04-10 国立大学法人德岛大学 新抗cd98抗体及其用途
CA2796055A1 (fr) 2010-04-15 2011-10-20 Amgen Inc. Proteines de liaison au recepteur de fgf humain et a ?-klotho
WO2011131626A1 (fr) 2010-04-19 2011-10-27 Medizinische Universität Innsbruck Tmem195 code pour l'activité alkylglycérol monooxygénase dépendante de la tétrahydrobioptérine
CA2796756A1 (fr) 2010-04-22 2011-10-27 Intra-Cellular Therapies, Inc. Pyrido(3',4':4,5)pyrrolo(1,2,3-de)quinoxalines substituees destinees au traitement de troubles du systeme nerveux central
GB201007531D0 (en) 2010-05-05 2010-06-23 Imp Innovations Ltd Composition
EP3181692A1 (fr) 2010-05-07 2017-06-21 Centre National De La Recherche Scientifique Ucp1 (thermogenin) - induisant des agents destinés à être utilisés dans le traitement d'un trouble de l'homéostasie énergétique
CA2800065A1 (fr) 2010-05-21 2011-11-24 Peptimed, Inc. Reactifs et methodes pour le traitement du cancer
WO2011149051A1 (fr) 2010-05-28 2011-12-01 中外製薬株式会社 Agent améliorant la réponse de lymphocytes t anti-tumoraux
WO2011149046A1 (fr) 2010-05-28 2011-12-01 独立行政法人国立がん研究センター Agent thérapeutique contre le cancer du pancréas
CN114010776A (zh) 2010-06-09 2022-02-08 疫苗技术股份有限公司 用于增强抗逆转录病毒治疗的hiv感染者的治疗性免疫
EA026675B1 (ru) 2010-06-16 2017-05-31 Эндорешерш, Инк. Способы лечения или предотвращения эстрогензависимых заболеваний
ES2486321T3 (es) 2010-06-18 2014-08-18 Xiberscience Gmbh Péptidos como agentes activos para estabilizar barreras biológicas
US8415307B1 (en) 2010-06-23 2013-04-09 Biosource Pharm, Inc. Antibiotic compositions for the treatment of gram negative infections
WO2011161531A1 (fr) 2010-06-24 2011-12-29 Torrent Pharmaceuticals Limited Composition pharmaceutique contenant de la goséréline pour un implant in situ
US9211175B2 (en) 2010-07-08 2015-12-15 Covidien Lp Self-detachable medical devices
CN103119062A (zh) 2010-07-16 2013-05-22 埃博灵克斯股份有限公司 修饰的单结构域抗原结合分子及其应用
FR2962646B1 (fr) 2010-07-16 2012-06-22 Sofradim Production Prothese avec element radio-opaque
UY33517A (es) 2010-07-19 2012-02-29 Astrazeneca Ab Depósito farmacéutico para 5-fluoro-2-[[(1S)-1-(5-fluoro-2-piridil)etil]amino]-6-[(5-isopropoxi-1H-pirazol-3-il)amino]piridin-3-carbonitrilo?.
EA030886B1 (ru) 2010-08-17 2018-10-31 Амбркс, Инк. Модифицированные полипептиды релаксина, содержащие некодируемую в природе аминокислоту, связанную с полимером, и их применение
US9567386B2 (en) 2010-08-17 2017-02-14 Ambrx, Inc. Therapeutic uses of modified relaxin polypeptides
EP2611868B1 (fr) 2010-08-30 2020-01-08 Surmodics Pharmaceuticals, Inc. Terpolymères biodégradables et mélanges de terpolymères comme adhésifs sensibles à la pression
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
TWI480288B (zh) 2010-09-23 2015-04-11 Lilly Co Eli 牛顆粒細胞群落刺激因子及其變體之調配物
EP2623592B1 (fr) 2010-09-28 2019-05-15 NB Health Laboratory Co. Ltd. Anticorps anti-ccr7 humain, hybridome, composition thérapeutique et vecteur à anticorps immobilisé
MX2013003599A (es) 2010-10-01 2013-07-29 Biogen Idec Inc Interferon-beta para uso como monoterapia o en combinacion con otras terapias de cancer.
US9572907B2 (en) 2010-10-01 2017-02-21 Covidien Lp Implantable polymeric films
US8920867B2 (en) 2010-10-19 2014-12-30 Covidien Lp Methods of forming self-supporting films for delivery of therapeutic agents
US9861590B2 (en) 2010-10-19 2018-01-09 Covidien Lp Self-supporting films for delivery of therapeutic agents
US8632839B2 (en) 2010-10-19 2014-01-21 Covidien Lp Methods of forming self-supporting films for delivery of therapeutic agents
CN103491978A (zh) 2010-10-25 2014-01-01 明尼苏达大学评议会 用于治疗成胶质细胞瘤的治疗组合物
CA2815181C (fr) 2010-10-27 2020-09-15 William Gleason Richards Anticorps anti-dkk1 et leurs procedes d'utilisation
BR112013010911A2 (pt) 2010-11-01 2017-05-02 Peptimed Inc composições de um sistema à base de peptídeo para direcionamento para céllas específicas
GB201019467D0 (en) 2010-11-17 2010-12-29 Biotecnol Sa Therapeutic agent
TWI452136B (zh) 2010-11-17 2014-09-11 中外製藥股份有限公司 A multiple specific antigen-binding molecule that replaces the function of Factor VIII in blood coagulation
US9023791B2 (en) 2010-11-19 2015-05-05 Novartis Ag Fibroblast growth factor 21 mutations
JP6033229B2 (ja) 2010-11-24 2016-11-30 レクシコン ファーマシューティカルズ インコーポレイテッド Ｎｏｔｕｍペクチンアセチルエステラーゼと結合する抗体
PT3434767T (pt) 2010-11-30 2026-01-23 Chugai Pharmaceutical Co Ltd Agente terapêutico indutor de citotoxicidade
PL2657252T3 (pl) 2010-12-23 2017-08-31 Hanall Biopharma Co., Ltd. Modyfikowany polipeptyd ludzkiego receptora-1 czynnika martwicy nowotworu lub jego fragment i sposób ich wytwarzania
WO2012092539A2 (fr) 2010-12-31 2012-07-05 Takeda Pharmaceutical Company Limited Anticorps contre dll4 et leurs utilisations
US9144634B2 (en) 2011-01-14 2015-09-29 Covidien Lp Medical device with intrapore films
SG10201600531TA (en) 2011-01-24 2016-02-26 Univ Singapore Pathogenic mycobacteria-derived mannose-capped lipoarabinomannan antigen binding proteins
US9708366B2 (en) 2011-01-27 2017-07-18 Neuren Pharmaceuticals Ltd. Treatment of fragile X syndrome using glycyl-L-2-methylprolyl-L-glutamate
EA201391248A1 (ru) 2011-03-01 2014-05-30 Эмджен Инк. Биспецифические связывающие агенты
AU2012225248A1 (en) 2011-03-10 2013-09-19 Genentech, Inc. Treatment of disorders with altered vascular barrier function
US10059746B2 (en) 2011-04-04 2018-08-28 University Of Iowa Research Foundation Methods of improving vaccine immunogenicity
US8628773B2 (en) 2011-04-07 2014-01-14 Amgen Inc. Antigen binding proteins
EP2694092B1 (fr) 2011-04-08 2017-01-04 Amgen Inc. Méthode de traitement ou d'amélioration de troubles métaboliques à l'aide du facteur 15 de différenciation de croissance (gdf-15)
HUE046004T2 (hu) 2011-04-25 2020-01-28 Shan Dong Luye Pharm Co Ltd Risperidon nyújtott hatóanyagleadású mikroszféra készítmény
ES2666303T3 (es) 2011-04-29 2018-05-03 University Of Washington Composiciones terapéuticas de nucleasa y métodos
EP2704735A1 (fr) 2011-05-03 2014-03-12 Genentech, Inc. Agents d'interruption vasculaire et utilisations associées
WO2012151343A1 (fr) 2011-05-04 2012-11-08 Balance Therapeutics, Inc. Dérivés de pentylènetétrazole
AU2012254160A1 (en) 2011-05-10 2013-11-21 Amgen Inc. Method of identifying compounds that specifically modulate the interaction of FGFR1 and beta-Klotho
JOP20200043A1 (ar) 2011-05-10 2017-06-16 Amgen Inc طرق معالجة أو منع الاضطرابات المختصة بالكوليسترول
CN103648489A (zh) 2011-05-11 2014-03-19 儿童医疗中心有限公司 多抗原提呈免疫原性组合物及其方法和用途
US9574002B2 (en) 2011-06-06 2017-02-21 Amgen Inc. Human antigen binding proteins that bind to a complex comprising β-Klotho and an FGF receptor
US9133082B2 (en) 2011-06-14 2015-09-15 Bikam Pharmaceuticals, Inc. Opsin-binding ligands, compositions and methods of use
US20140227265A1 (en) 2011-06-17 2014-08-14 Amgen Inc. Method of treating or ameliorating metabolic disorders using clec-2
FR2977790B1 (fr) 2011-07-13 2013-07-19 Sofradim Production Prothese pour hernie ombilicale
WO2013016220A1 (fr) 2011-07-22 2013-01-31 Amgen Inc. Récepteur a de il-il-17 requis pour biologie il-17c
US8579924B2 (en) 2011-07-26 2013-11-12 Covidien Lp Implantable devices including a mesh and a pivotable film
WO2013017656A1 (fr) 2011-08-02 2013-02-07 Medizinische Universität Wien Antagonistes de ribonucléases pour traiter l'obésité
WO2013025939A2 (fr) 2011-08-16 2013-02-21 Indiana University Research And Technology Corporation Composés et méthodes de traitement du cancer par l'inhibition du récepteur de l'urokinase
WO2013025479A1 (fr) 2011-08-16 2013-02-21 Emory University Agents spécifiques de liaison à jaml, anticorps, et leurs utilisations associées
CA2843369A1 (fr) 2011-08-16 2013-02-21 Evotec (Munchen) Gmbh Marqueurs de sensibilite a un inhibiteur de kinase de la famille src
EP2744508B1 (fr) 2011-08-19 2017-11-08 Children's Medical Center Corporation Protéine de liaison du vegf pour le blocage de l'angiogenèse
US9782957B2 (en) 2011-08-24 2017-10-10 Covidien Lp Medical device films
MX2014002260A (es) 2011-08-31 2014-08-18 Amgen Inc Factor de crecimiento de fibroblasto 21 para usar en el tratamiento de diabetes tipo 1.
WO2013039916A1 (fr) 2011-09-12 2013-03-21 The United States Of America, Represented By The Secretary, Dept. Of Health And Human Services Compositions et méthodes de traitement et de détection améliorée de tumeurs non pituitaires
MX353958B (es) 2011-09-22 2018-02-07 Amgen Inc Proteinas de union al antigeno cd27l.
UY34347A (es) 2011-09-26 2013-04-30 Novartis Ag Proteínas de función dual para tratar trastornos metabólicos
TWI593708B (zh) 2011-09-26 2017-08-01 諾華公司 治療代謝病症之融合蛋白質
EP2752200B1 (fr) 2011-09-30 2023-11-01 Chugai Seiyaku Kabushiki Kaisha Molécule de liaison d'un antigène induisant une réponse immunitaire pour cibler l'antigène
DE102011114864A1 (de) 2011-10-05 2013-04-11 Acino Ag Verfahren zur Herstellung einer homogenen Pulvermischung und Verfahren zur Herstellung eines Implantats sowie Implantat
WO2013053076A1 (fr) 2011-10-10 2013-04-18 Zensun （Shanghai）Science & Technology Limited Compositions et procédés pour le traitement de l'insuffisance cardiaque
US8906860B2 (en) 2011-10-14 2014-12-09 The Board Of Trustees Of The University Of Illinois Methods and compositions inhibiting tumor cell proliferation
WO2013056255A1 (fr) 2011-10-14 2013-04-18 The Board Of Trustees Of The University Of Illinois Procédés et compositions pour inhiber la prolifération de cellules tumorales
CA2856703A1 (fr) 2011-10-19 2013-04-25 Bikam Pharmaceuticals, Inc. Ligands de liaison a une opsine, compositions et procedes d'utilisation
US8932621B2 (en) 2011-10-25 2015-01-13 Covidien Lp Implantable film/mesh composite
US9005308B2 (en) 2011-10-25 2015-04-14 Covidien Lp Implantable film/mesh composite for passage of tissue therebetween
US9179994B2 (en) 2011-10-25 2015-11-10 Covidien Lp Implantable film/mesh composite
TWI679212B (zh) 2011-11-15 2019-12-11 美商安進股份有限公司 針對ｂｃｍａ之e3以及ｃｄ３的結合分子
PE20141937A1 (es) 2011-11-16 2014-12-18 Amgen Inc Metodos para tratar trastornos relacionados con mutante viii de eliminacion de factor de crecimiento epidermico
GR1007832B (el) 2011-11-21 2013-02-14 Ιδρυμα Ιατροβιολογικων Ερευνων Ακαδημιας Αθηνων, Αδρανοποιητες της ακτιβινης και χρηση τους για την θεραπεια ασθενειων που σχετιζονται με παρεκκλινουσα ενεργοποιηση της "αμυντικης αποκρισης του ξενιστη"
ES3018133T3 (en) 2011-11-30 2025-05-14 Univ Emory Jak inhibitors for use in the prevention or treatment of a viral disease caused by a coronaviridae
WO2013082000A1 (fr) 2011-11-30 2013-06-06 Bikam Pharmaceuticals, Inc. Ligands de liaison aux opsines, compositions et procédés d'utilisation
AU2012346537A1 (en) 2011-12-01 2014-07-17 Bikam Pharmaceuticals, Inc. Opsin-binding ligands, compositions and methods of use
JP6635655B2 (ja) 2011-12-08 2020-01-29 アムジエン・インコーポレーテツド ヒトｌｃａｔ抗原結合タンパク質および治療法におけるそれらの使用
US9376715B2 (en) 2011-12-09 2016-06-28 Roche Molecular Systems, Inc Methods for detecting mutations in the catalytic subunit of the phosphoinositol-3 kinase (PIK3CA) gene
WO2013096516A1 (fr) 2011-12-19 2013-06-27 Xoma Technology Ltd. Méthodes de traitement de l'acné
HK1203384A1 (en) 2011-12-19 2015-12-11 Amgen Inc. Variant activin receptor polypeptides, alone or in combination with chemotherapy, and uses thereof
EP3560509B1 (fr) 2011-12-22 2024-01-31 Children's Medical Center Corporation Peptides dérivés de la saposine-a et leurs utilisations
JP2015509091A (ja) 2012-01-09 2015-03-26 ザ スクリプス リサーチ インスティテュート ヒト化抗体
CA2863224A1 (fr) 2012-01-09 2013-07-18 The Scripps Research Institute Regions determinant la complementarite ultralongues et utilisations associees
WO2013106572A1 (fr) 2012-01-11 2013-07-18 Arizona Board Of Regents, A Body Corporate Of The State Of Arizona Acting For And On Behalf Of Arizona State University Fragments d'anticorps bispécifiques pour protéines associées à une maladie neurologique, et procédés d'utilisation
EP3683228A3 (fr) 2012-01-26 2020-07-29 Amgen Inc. Polypeptides du facteur de croissance et de différenciation 15 (gdf-15)
EP2626066A1 (fr) 2012-02-10 2013-08-14 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Polythérapie comprenant des inhibiteurs VEGFR-2 sélectifs et inhibiteurs MEK
CN104271772A (zh) 2012-03-29 2015-01-07 科罗拉多州立大学董事会,公司实体 点击核酸
US10206769B2 (en) 2012-03-30 2019-02-19 Covidien Lp Implantable devices including a film providing folding characteristics
US8753643B1 (en) 2012-04-11 2014-06-17 Life-Science Innovations, Llc Spray dried compositions and methods of use
KR20140146192A (ko) 2012-04-14 2014-12-24 인트라-셀룰라 써래피스, 인코퍼레이티드. 유기 화합물
EP2843051B1 (fr) 2012-04-23 2018-06-06 GeneFrontier Corporation Anticorps anti-cd69 humain, et application médicale de celui-ci
EA039663B1 (ru) 2012-05-03 2022-02-24 Амген Инк. Применение антитела против pcsk9 для снижения сывороточного холестерина лпнп и лечения связанных с холестерином расстройств
KR102142161B1 (ko) 2012-05-14 2020-08-06 바이오젠 엠에이 인코포레이티드 운동 뉴런 관련 병태 치료용 lingo-2 길항제
AR091069A1 (es) 2012-05-18 2014-12-30 Amgen Inc Proteinas de union a antigeno dirigidas contra el receptor st2
US9844582B2 (en) 2012-05-22 2017-12-19 Massachusetts Institute Of Technology Synergistic tumor treatment with extended-PK IL-2 and therapeutic agents
FR2992662B1 (fr) 2012-06-28 2014-08-08 Sofradim Production Tricot avec picots
FR2992547B1 (fr) 2012-06-29 2015-04-24 Sofradim Production Prothese pour hernie
CA2877441A1 (fr) 2012-07-02 2014-01-09 Medizinische Universitat Wien Produit de separation du complement c4d pour le traitement d'affections inflammatoires
EP2687225A1 (fr) 2012-07-19 2014-01-22 Alfact Innovation Protéine HIP/PAP et ses dérivés pour une utilisation dans le traitement du cancer
KR20200108932A (ko) 2012-07-25 2020-09-21 에스에이알코드 바이오사이언스 인코포레이티드 Lfa-1 저해제 및 그의 다형체
DE102013011399A1 (de) 2012-07-31 2014-02-06 Amw Gmbh Implantat mit Risperidon
EP2695950A1 (fr) 2012-08-10 2014-02-12 Blackfield AG Marqueurs pour la réactivité à un inhibiteur du récepteur du facteur de croissance des fibroblastes
US9119858B2 (en) 2012-08-21 2015-09-01 Genesys Research Institute, Inc. Compositions and methods for treating or preventing anthracycline induced cardiotoxicity
US9309318B2 (en) 2012-10-17 2016-04-12 Amgen, Inc. Compositions relating to anti-IL-21 receptor antibodies
PL2908865T3 (pl) 2012-10-17 2019-08-30 Vascular Biogenics Ltd. Adenowirus wykazujący ekspresję chimery Fas i jego zastosowanie w sposobach leczenia raka
US9845364B2 (en) 2012-11-09 2017-12-19 Genefrontier Corporation Anti-ADAM28 antibody for treating cancer
UY35148A (es) 2012-11-21 2014-05-30 Amgen Inc Immunoglobulinas heterodiméricas
KR102291355B1 (ko) 2012-11-30 2021-08-19 에프. 호프만-라 로슈 아게 Pd-l1 억제제 공동치료를 필요로 하는 환자의 식별방법
TW201425336A (zh) 2012-12-07 2014-07-01 Amgen Inc Ｂｃｍａ抗原結合蛋白質
CA2895198A1 (fr) 2012-12-20 2014-06-26 Medimmune, Llc Formulation d'anticorps liquide ayant des proprietes d'agregation ameliorees
JO3519B1 (ar) 2013-01-25 2020-07-05 Amgen Inc تركيبات أجسام مضادة لأجل cdh19 و cd3
EP2948478B1 (fr) 2013-01-25 2019-04-03 Amgen Inc. Anticorps ciblant cdh19 pour un mélanome
AU2014212014A1 (en) 2013-02-01 2015-08-27 Amgen Inc. Administration of an anti-activin-A compound to a subject
US11576958B2 (en) 2013-02-07 2023-02-14 Children's Medical Center Corporation Protein antigens that provide protection against pneumococcal colonization and/or disease
WO2014131024A2 (fr) 2013-02-25 2014-08-28 Synergy Pharmaceuticals Inc. Agonistes de la guanylate cyclase et applications associées
EA033537B1 (ru) 2013-03-11 2019-10-31 Durect Corp Инъекционная композиция с контролируемым высвобождением, содержащая жидкий носитель с высокой вязкостью
US20140308352A1 (en) 2013-03-11 2014-10-16 Zogenix Inc. Compositions and methods involving polymer, solvent, and high viscosity liquid carrier material
US9458246B2 (en) 2013-03-13 2016-10-04 Amgen Inc. Proteins specific for BAFF and B7RP1
PH12022550138A1 (en) 2013-03-13 2023-03-06 Amgen Inc Proteins specific for baff and b7rp1 and uses thereof
EP2970451A1 (fr) 2013-03-14 2016-01-20 Amgen Inc. Protéines de liaison à l'antigène chrdl-1 et procédés de traitement
US9580486B2 (en) 2013-03-14 2017-02-28 Amgen Inc. Interleukin-2 muteins for the expansion of T-regulatory cells
US9708322B2 (en) 2013-03-15 2017-07-18 Intra-Cellular Therapies, Inc. Substituted pyrido[3',4':4,5]pyrrolo[1,2,3-de]quinoxalines for inhibiting serotonin reuptake transporter activity
US9708375B2 (en) 2013-03-15 2017-07-18 Amgen Inc. Inhibitory polypeptides specific to WNT inhibitors
AU2014235215A1 (en) 2013-03-15 2015-10-01 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase and their uses
AU2014235209B2 (en) 2013-03-15 2018-06-14 Bausch Health Ireland Limited Guanylate cyclase receptor agonists combined with other drugs
EP2970446A1 (fr) 2013-03-15 2016-01-20 Amgen Research (Munich) GmbH Constructions d'anticorps pour m2 et cd3 de grippe
PL2970449T3 (pl) 2013-03-15 2020-04-30 Amgen Research (Munich) Gmbh Jednołańcuchowe cząsteczki wiążące zawierające N-końcowy ABP
US9850297B2 (en) 2013-03-15 2017-12-26 Amgen Inc. Secreted frizzle-related protein 5 (SFRP5) binding proteins
EP2970483A2 (fr) 2013-03-15 2016-01-20 Amgen Inc. Procédés et compositions liés aux protéines de liaison à un antigène anti-ccr7
TW201521769A (zh) 2013-03-15 2015-06-16 Durect Corp 具有流變改質劑以減少溶解變異性之組成物
US9474792B2 (en) 2013-03-15 2016-10-25 Amgen Inc. Method of treating metabolic disorders using PLA2G12A polypeptides and PLA2G12A mutant polypeptides
CA2906737C (fr) 2013-03-15 2023-08-15 Amgen Inc. Anticorps anti-pac1 humains
ES2716384T3 (es) * 2013-04-18 2019-06-12 Shandong luye pharmaceutical co ltd Composición farmacéutica de microesferas de liberación sostenida de goserelina
EP3461909A1 (fr) 2013-05-21 2019-04-03 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Isoformes spécifiques de gata6 et nkx2-1 en tant que nouveaux marqueurs pour les approches de diagnostic et de thérapie du cancer et en tant que cibles pour la thérapie anticancéreuse
EP3895724B1 (fr) 2013-05-22 2025-06-25 Zensun (Shanghai) Science and Technology, Co., Ltd. Libération prolongée de neuréguline pour le traitement de l'insuffisance cardiaque
WO2014193800A2 (fr) 2013-05-28 2014-12-04 The Johns Hopkins University Aptamères utiles dans le traitement de la drépanocytose
HUE056580T2 (hu) 2013-05-30 2022-02-28 Kiniksa Pharmaceuticals Ltd Onkosztatin-M-receptor antigénjét kötõ fehérjék
EP2810648A1 (fr) 2013-06-04 2014-12-10 Daniel Rauh Interaction domaine-domaine de ciblage pour l'identification des modulateurs de kinase
US10782290B2 (en) 2013-06-11 2020-09-22 National Center Of Neurology And Psychiatry Method for predicting post-therapy prognosis of relapsing-remitting multiple sclerosis (RRMS) patient, and method for determining applicability of novel therapy
JP6869720B2 (ja) 2013-06-13 2021-05-12 アンチセンス セラピューティクス リミテッド 併用療法
US10154971B2 (en) 2013-06-17 2018-12-18 Adamas Pharma, Llc Methods of administering amantadine
EP2835135A3 (fr) 2013-06-19 2015-06-24 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Berlin Moyens et procédés pour traiter une infection par Pseudomonas
CA2916259C (fr) 2013-06-28 2024-02-20 Amgen Inc. Procedes de traitement d'une hypercholesterolemie familiale homozygote
WO2015017146A2 (fr) 2013-07-18 2015-02-05 Fabrus, Inc. Anticorps à régions de détermination de complémentarité ultralongues
CA2918370A1 (fr) 2013-07-18 2015-01-22 Fabrus, Inc. Anticorps humanises comprenant des regions determinant la complementarite ultralongues
US9862752B2 (en) 2013-07-31 2018-01-09 Amgen Inc. Growth differentiation factor 15 (GDF-15) constructs
WO2015022326A1 (fr) 2013-08-12 2015-02-19 Xiber Science Gmbh Peptides en tant qu'agents actifs pour le traitement d'un dysfonctionnement du greffon primaire
TW201605896A (zh) 2013-08-30 2016-02-16 安美基股份有限公司 Gitr抗原結合蛋白
EP3041863A4 (fr) 2013-09-05 2017-08-16 Amgen Inc. Molécules contenant des fc et présentant des profils de glycoforme prévisibles, uniformes et reproductibles
CA2923835C (fr) 2013-09-11 2022-11-29 The Administrators Of The Tulane Educational Fund Nouveaux amides anthraniliques et utilisation de ces derniers
JP6822839B2 (ja) 2013-09-13 2021-01-27 ザ・スクリップス・リサーチ・インスティテュート 修飾された治療剤、及びその組成物
AR097648A1 (es) 2013-09-13 2016-04-06 Amgen Inc Combinación de factores epigenéticos y compuestos biespecíficos que tienen como diana cd33 y cd3 en el tratamiento de leucemia mieloide
MX348980B (es) 2013-09-16 2017-07-05 Cemm-Forschungszentrum Für Molekulare Medizin Gmbh Calreticulina mutante para la diagnosis de malignidades mieloides.
GB201316738D0 (en) 2013-09-20 2013-11-06 Rainbow Medical Engineering Ltd Implantable Medical Devices
TWI673063B (zh) 2013-09-20 2019-10-01 日商中外製藥股份有限公司 抗蛋白ｃ抗體之出血性疾病的治療
US9957506B2 (en) 2013-09-25 2018-05-01 Cornell University Compounds for inducing anti-tumor immunity and methods thereof
WO2015051304A1 (fr) 2013-10-04 2015-04-09 Aptose Biosciences Inc. Compositions, biomarqueurs et leur utilisation dans le traitement du cancer
JP6661531B2 (ja) 2013-10-10 2020-03-11 シナジー ファーマシューティカルズ インコーポレイテッド オピオイド誘発性機能障害の治療に有用なグアニル酸シクラーゼのアゴニスト
CN105829349B (zh) 2013-10-15 2023-02-03 斯克利普斯研究所 肽嵌合抗原受体t细胞开关和其用途
CN105814083A (zh) 2013-10-15 2016-07-27 加州生物医学研究所 嵌合抗原受体t细胞开关和其用途
PT3057992T (pt) 2013-10-15 2024-07-10 Univ Keio Anticorpo humano contra espécies de adamts do tipo agrecanase para terapêuticas de doenças relacionadas com agrecanase
EP3057605A1 (fr) 2013-10-18 2016-08-24 Novartis AG Méthodes de traitement du diabete et de troubles associés
JP6495270B2 (ja) 2013-10-30 2019-04-03 ザ ユニバーシティ オブ ウェスタン オーストラリア 神経保護ペプチドを含有する医薬組成物
HRP20192080T1 (hr) 2013-10-31 2020-02-07 Resolve Therapeutics, Llc Terapeutske fuzije nukleaza-albumine i postupci
GB201319374D0 (en) 2013-11-01 2013-12-18 Univ Nottingham Glycans as functional cancer targets abd antibodies thereto
KR102373288B1 (ko) 2013-12-03 2022-03-10 인트라-셀룰라 써래피스, 인코퍼레이티드. 신규한 방법
KR102455171B1 (ko) 2013-12-18 2022-10-14 더 스크립스 리서치 인스티튜트 변형된 치료제, 스테이플드 펩티드 지질 접합체, 및 이의 조성물
CN103965357B (zh) 2013-12-31 2016-08-17 嘉和生物药业有限公司 一种抗人rankl抗体
WO2015110930A1 (fr) 2014-01-24 2015-07-30 Pfizer Inc. Protéines de récepteur d'interleukine 21 modifiées
US10189908B2 (en) 2014-02-05 2019-01-29 The University Of Chicago Chimeric antigen receptors recognizing cancer-specific TN glycopeptide variants
WO2015121457A1 (fr) 2014-02-13 2015-08-20 Westphal Sören Fgf-8 destiné à être utilisé dans le traitement de maladies ou de troubles de l'homéostasie énergétique
WO2015127134A2 (fr) 2014-02-20 2015-08-27 Allergan, Inc. Anticorps anti-composant c5 de du systeme de complement
CN110724691A (zh) 2014-02-27 2020-01-24 阿勒根公司 补体因子Bb抗体
CA2941716A1 (fr) 2014-03-07 2015-09-11 The Johns Hopkins University Inhibiteurs de la demethylase (lsd1) specifique d'une lysine d'histone et d'histones desacetylases (hdac)
WO2015138919A1 (fr) 2014-03-14 2015-09-17 The University Of North Carolina At Chapel Hill Petites molécules pour inhiber la fertilité mâle
WO2015153639A1 (fr) 2014-03-31 2015-10-08 The Johns Hopkins University Utilisation de bactéries, produits bactériens et autres entités immunomodulatrices en association avec des anticorps anti-ctla-4 et/ou anti-pd-1 pour le traitement de tumeurs malignes solides
CA2944755A1 (fr) 2014-04-04 2015-10-08 Intra-Cellular Therapies, Inc. Composes organiques
US10077267B2 (en) 2014-04-04 2018-09-18 Intra-Cellular Therapies, Inc. Organic compounds
US10507227B2 (en) 2014-04-15 2019-12-17 The Hospital For Sick Children Cationic antimicrobial peptides
US9956164B2 (en) 2014-04-16 2018-05-01 Veyx-Pharma Gmbh Veterinary pharmaceutical composition and use thereof
US20170073690A1 (en) 2014-05-15 2017-03-16 CEMM - Forschungzentrum Fuer Molekulare Medizin GMBH Antagonists of slc38a9 and their use in therapy
WO2015179415A1 (fr) 2014-05-19 2015-11-26 Novartis Ag Méthodes de traitement de l'anorexie
WO2015184260A2 (fr) 2014-05-30 2015-12-03 The Johns Hopkins University Méthodes de traitement de troubles mendélien de la machinerie épigénétiques
WO2015187779A1 (fr) 2014-06-03 2015-12-10 Xbiotech, Inc. Compositions et méthodes de traitement et de prévention des infections à staphylococcus aureus
WO2015191554A1 (fr) 2014-06-09 2015-12-17 Intra-Cellular Therapies, Inc. Composés et leurs procédés d'utilisation pour traiter la schizophrénie
MX381052B (es) 2014-06-09 2025-03-12 Ultragenyx Pharmaceutical Inc El control efectivo y eficaz del fosfato serico para una osificacion optima.
PE20170471A1 (es) 2014-06-13 2017-05-14 Santa Maria Biotherapeutics Inc Polipeptidos receptores formulados y metodos relacionados
TWI831106B (zh) 2014-06-20 2024-02-01 日商中外製藥股份有限公司 用於因第viii凝血因子及/或活化的第viii凝血因子的活性降低或欠缺而發病及/或進展的疾病之預防及/或治療之醫藥組成物
WO2016007919A2 (fr) 2014-07-11 2016-01-14 Regents Of The University Of Minnesota Fragments d'anticorps pour détecter un cancer et méthodes d'utilisation
EP2977758A1 (fr) 2014-07-24 2016-01-27 Université De Nice Sophia Antipolis Procédés et kits pour surveiller la néphropathie membraneuse
UY36245A (es) 2014-07-31 2016-01-29 Amgen Res Munich Gmbh Constructos de anticuerpos para cdh19 y cd3
EP3174901B1 (fr) 2014-07-31 2019-06-26 Amgen Research (Munich) GmbH Constructions optimisées d'anticorps monocaténaires, bispécifiques, spécifiques d'espèces croisées
CA2957717C (fr) 2014-08-12 2021-10-19 Massachusetts Institute Of Technology Traitement tumoral synergique a l'aide d'il-2 et d'une proteine de fusion fc liant l'integrine
WO2016025647A1 (fr) 2014-08-12 2016-02-18 Massachusetts Institute Of Technology Traitement tumoral synergique avec l'il-2, un anticorps thérapeutique, et un vaccin contre le cancer
US10465188B2 (en) 2014-08-22 2019-11-05 Auckland Uniservices Limited Channel modulators
US10111898B2 (en) 2014-08-27 2018-10-30 Peptimed, Inc. Anti-tumor compositions and methods
WO2016040767A2 (fr) 2014-09-12 2016-03-17 Amgen Inc. Anticorps et épitopes chrdl-1
MA40764A (fr) 2014-09-26 2017-08-01 Chugai Pharmaceutical Co Ltd Agent thérapeutique induisant une cytotoxicité
JP6821560B2 (ja) 2014-10-21 2021-01-27 サイクロン ファーマシューティカルズ インターナショナル エルティーディー．Ｓｃｉｃｌｏｎｅ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｔｅｒｎａｔｉｏｎａｌ Ｌｔｄ． 免疫刺激剤による癌治療
CN114805532A (zh) 2014-10-24 2022-07-29 百时美施贵宝公司 修饰的fgf-21多肽及其用途
WO2016069889A1 (fr) 2014-10-31 2016-05-06 Resolve Therapeutics, Llc Hybrides nucléase-transferrine à visée thérapeutique et procédés associés
WO2016079321A1 (fr) 2014-11-20 2016-05-26 Cemm Forschungszentrum Für Molekulare Medizin Gmbh Antagonistes de setdb2 pour leur utilisation dans la thérapie de maladies infectieuses
EP3085709B1 (fr) 2014-12-28 2019-08-21 Genor Biopharma Co., Ltd Anticorps anti-rankl humain humanisé, composition pharmaceutique et son utilisation
JP2018504400A (ja) 2015-01-08 2018-02-15 バイオジェン・エムエイ・インコーポレイテッドＢｉｏｇｅｎ ＭＡ Ｉｎｃ． Ｌｉｎｇｏ‐１拮抗薬及び脱髄障害の治療のための使用
WO2016123143A1 (fr) 2015-01-26 2016-08-04 The University Of Chicago Lymphocytes t à récepteur d'antigène chimérique (car) reconnaissant le récepteur il 13rα2 spécifique au cancer
CN107683289B (zh) 2015-01-26 2021-08-06 芝加哥大学 IL13Rα2结合剂和其在癌症治疗中的用途
US9744239B2 (en) 2015-01-30 2017-08-29 Par Pharmaceutical, Inc. Vasopressin formulations for use in treatment of hypotension
RU2722832C2 (ru) 2015-02-23 2020-06-04 Сигалл Терапьютикс Сас Неприродные семафорины класса 3 и их медицинское применение
US10800828B2 (en) 2015-03-26 2020-10-13 The Scripps Research Institute Switchable non-scFv chimeric receptors, switches, and methods of use thereof to treat cancer
CR20170510A (es) 2015-04-10 2018-02-26 Amgen Inc Muteínas de interuquina 2 para la expansión de células t regulatorias
US11091546B2 (en) 2015-04-15 2021-08-17 The Scripps Research Institute Optimized PNE-based chimeric receptor T cell switches and uses thereof
CN107750255B (zh) 2015-04-17 2022-08-30 安进研发（慕尼黑）股份有限公司 用于cdh3和cd3的双特异性抗体构建体
EP3294072A4 (fr) 2015-05-15 2019-03-13 The Johns Hopkins University Nouveau complément alimentaire prénatal de fluorure
US20160361380A1 (en) 2015-06-12 2016-12-15 Nymox Corporation Combination compositions for treating disorders requiring removal or destruction of unwanted cellular proliferations
WO2016205488A1 (fr) 2015-06-17 2016-12-22 The California Institute For Biomedical Research Agents thérapeutiques modifiés et compositions associées
WO2017007955A1 (fr) 2015-07-07 2017-01-12 The Research Foundation For The State University Of New York Utilisation d'amines carboxyboranes pour l'administration thérapeutique de monoxyde de carbone et en tant que système d'administration de médicament général en présence d'espèces réactives de l'oxygène
ES2546566B2 (es) * 2015-07-23 2016-09-14 Universidade De Santiago De Compostela Sistema para la administración de sustancias biológicamente activas preparado por técnicas de espumado empleando gases comprimidos o fluidos supercríticos
EA039859B1 (ru) 2015-07-31 2022-03-21 Эмджен Рисерч (Мюник) Гмбх Биспецифические конструкты антител, связывающие egfrviii и cd3
TWI796283B (zh) 2015-07-31 2023-03-21 德商安美基研究（慕尼黑）公司 Ｍｓｌｎ及ｃｄ３抗體構築體
TWI829617B (zh) 2015-07-31 2024-01-21 德商安美基研究（慕尼黑）公司 Ｆｌｔ３及ｃｄ３抗體構築體
TWI717375B (zh) 2015-07-31 2021-02-01 德商安美基研究（慕尼黑）公司 Ｃｄ７０及ｃｄ３抗體構築體
CN108135872A (zh) 2015-07-31 2018-06-08 约翰霍普金斯大学 用于治疗认知缺陷的谷氨酰胺拮抗剂
US10842763B2 (en) 2015-07-31 2020-11-24 The Johns Hopkins University Methods for cancer and immunotherapy using prodrugs of glutamine analogs
TWI793062B (zh) 2015-07-31 2023-02-21 德商安美基研究（慕尼黑）公司 Ｄｌｌ３及ｃｄ３抗體構築體
EA034571B1 (ru) 2015-07-31 2020-02-21 Дзе Джонс Хопкинс Юниверсити Пролекарства аналогов глутамина
CN108135875B (zh) 2015-07-31 2021-12-31 约翰霍普金斯大学 用于治疗代谢重编程病症的方法和组合物
TWI744242B (zh) 2015-07-31 2021-11-01 德商安美基研究（慕尼黑）公司 Egfrviii及cd3抗體構築體
JO3620B1 (ar) 2015-08-05 2020-08-27 Amgen Res Munich Gmbh مثبطات نقطة فحص مناعية للاستخدام في علاج سرطانات محمولة عبر الدم
US20180280474A1 (en) 2015-10-01 2018-10-04 Amgen Inc. Treatment of bile acid disorders
MX2018005232A (es) 2015-11-03 2018-08-15 Ambrx Inc Anticuerpos anti-cd3 novedosos y sus usos.
AU2016349897B2 (en) 2015-11-03 2021-11-04 Regents Of The University Of Minnesota CD200 inhibitors and methods of use thereof
JP2019503985A (ja) 2015-11-03 2019-02-14 グリコミメティクス， インコーポレイテッド モノクローナル抗体、造血幹細胞の産生のための方法および組成物、ならびにそれらを使用する方法
WO2017086367A1 (fr) 2015-11-18 2017-05-26 中外製薬株式会社 Polythérapie utilisant une molécule de liaison à l'antigène à rôle de redirection des cellules t, ciblant des cellules immunosupressives
WO2017086419A1 (fr) 2015-11-18 2017-05-26 中外製薬株式会社 Procédé pour renforcer la réponse immunitaire humorale
WO2017096262A1 (fr) 2015-12-04 2017-06-08 Jomoco, Corp. Compositions et procédés pour atténuer ou prévenir une réponse immunitaire à une molécule thérapeutique immunogène chez des primates non humains
DK3391902T5 (da) 2015-12-18 2024-09-23 Talengen Int Ltd Plasminogen til anvendelse i behandlingen af diabetisk angiokardiopati
UA127495C2 (uk) 2015-12-23 2023-09-13 Амджен Інк. Виділений антигензв'язуючий білок, який специфічно зв'язується з поліпептидом рецептора шлункового інгібіторного пептиду (gipr) людини, та фармацевтична композиція, яка його містить
WO2017110980A1 (fr) 2015-12-25 2017-06-29 中外製薬株式会社 Anticorps présentant une activité accrue et son procédé de modification
US10653744B2 (en) 2016-01-11 2020-05-19 Bausch Health Ireland Limited Formulations and methods for treating ulcerative colitis
JOP20170017B1 (ar) 2016-01-25 2021-08-17 Amgen Res Munich Gmbh تركيب صيدلي يتضمن تركيبات جسم مضاد ثنائي الاختصاص
PL3838274T3 (pl) 2016-01-26 2024-04-02 Intra-Cellular Therapies, Inc. Pochodna pirydo[3',4':4,5]pirolo[1,2,3-DE]chinoksaliny do zastosowania w leczeniu zaburzeń OUN
IL313507A (en) 2016-02-03 2024-08-01 Amgen Res Munich Gmbh Constructs of bispecific antibodies to BCMA and CD3 that bind to T cells, preparations containing the same and uses thereof
EA201891753A1 (ru) 2016-02-03 2019-01-31 Эмджен Рисерч (Мюник) Гмбх Биспецифические конструкции антител к psma и cd3, вовлекающие т-клетки
US10098909B2 (en) 2016-02-05 2018-10-16 University Of South Florida Ionic cocrystal of lithium, lispro, for the treatment of fragile X syndrome
US10729771B2 (en) 2016-02-10 2020-08-04 Rutgers, The State University Of New Jersey Anti-LAM and anti-PIM6/LAM monoclonal antibodies for diagnosis and treatment of Mycobacterium tuberculosis infections
EP3216458A1 (fr) 2016-03-07 2017-09-13 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Facteur de croissance endothéliale vasculaire (vegf-a)modifié et son utilisation médicale
US11072666B2 (en) 2016-03-14 2021-07-27 Chugai Seiyaku Kabushiki Kaisha Cell injury inducing therapeutic drug for use in cancer therapy
DK3407889T3 (da) 2016-03-25 2021-08-09 Intra Cellular Therapies Inc Organiske forbindelser og deres anvendelse til behandling og forebyggelse af lidelser i centralnervesystemet
US10682354B2 (en) 2016-03-28 2020-06-16 Intra-Cellular Therapies, Inc. Compositions and methods
JP7422480B2 (ja) 2016-05-04 2024-01-26 アムジエン・インコーポレーテツド 制御性ｔ細胞の増殖のためのインターロイキン－２変異タンパク質
US10183058B2 (en) 2016-06-17 2019-01-22 Nymox Corporation Method of preventing or reducing the progression of prostate cancer
CA3029627A1 (fr) 2016-07-01 2018-01-04 Resolve Therapeutics, Llc Fusions de binuclease optimisees
SG11201811760VA (en) 2016-07-06 2019-01-30 Durect Corp Oral dosage form with drug composition, barrier layer and drug layer
US10300145B2 (en) 2016-07-15 2019-05-28 Massachusetts Institute Of Technology Synthetic nanoparticles for delivery of immunomodulatory compounds
US10172910B2 (en) 2016-07-28 2019-01-08 Nymox Corporation Method of preventing or reducing the incidence of acute urinary retention
KR20190037261A (ko) 2016-08-08 2019-04-05 암젠 인크 항-스클레로스틴 항체를 사용한 결합 조직 부착 개선 방법
US10981976B2 (en) 2016-08-31 2021-04-20 University Of Rochester Human monoclonal antibodies to human endogenous retrovirus K envelope (HERV-K) and use thereof
PL3509637T3 (pl) 2016-09-06 2025-03-10 Chugai Seiyaku Kabushiki Kaisha Sposoby zastosowania dwuswoistego przeciwciała, które rozpoznaje czynnik krzepnięcia IX i/lub aktywowany czynnik krzepnięcia IX oraz czynnik krzepnięcia X i/lub aktywowany czynnik krzepnięcia X
US10532081B2 (en) 2016-09-07 2020-01-14 Nymox Corporation Method of ameliorating or preventing the worsening or the progression of symptoms of BPH
JP7048572B6 (ja) 2016-09-16 2023-12-20 リサーチ トライアングル インスティテュート テトラヒドロイソキノリンカッパーオピオイドアンタゴニスト
EP3525763B1 (fr) 2016-10-12 2025-03-05 Intra-Cellular Therapies, Inc. Dispersions solides amorphes
EP3529268B1 (fr) 2016-10-19 2025-02-26 The Scripps Research Institute Commutateurs de cellules effectrices à récepteurs chimériques d'antigène à fractions de ciblage humanisées et/ou à domaines d'interaction de récepteurs chimériques d'antigène optimisés et leurs utilisations
WO2018107686A1 (fr) 2016-12-15 2018-06-21 深圳瑞健生命科学研究院有限公司 Méthode de traitement de l'athérosclérose et de ses complications
JP7168990B2 (ja) 2016-12-15 2022-11-10 タレンゲン インターナショナル リミテッド 肥満症を予防および治療するための方法および薬物
CN110198732A (zh) 2016-12-15 2019-09-03 泰伦基国际有限公司 一种促进胰岛素受体底物-2表达的方法
JP7242057B2 (ja) 2016-12-15 2023-03-20 タレンゲン インターナショナル リミテッド 薬物性腎損傷を予防及び治療するための方法
TWI677348B (zh) 2016-12-15 2019-11-21 大陸商深圳瑞健生命科學研究院有限公司 一種改善心臟病變的方法
JP7213552B2 (ja) 2016-12-15 2023-01-27 タレンゲン インターナショナル リミテッド 肝の繊維化を予防及び治療するための方法
CA3047298C (fr) 2016-12-15 2023-12-12 Talengen International Limited Medicament pour la prevention et le traitement de l'osteoporose et ses utilisations
WO2018126140A1 (fr) 2016-12-29 2018-07-05 Intra-Cellular Therapies, Inc. Composés organiques
EP3562484B1 (fr) 2016-12-29 2021-08-25 Intra-Cellular Therapies, Inc. Dérivés de pyrido[3',4':4,5]pyrrolo[1,2,3-de]quinoxaline utiles dans les traitements de troubles du snc
EP3567054A4 (fr) 2017-01-06 2021-03-10 ABL Bio Inc. Anticorps anti-alpha-syn et son utilisation
BR112019013953A2 (pt) 2017-01-06 2020-02-11 Abl Bio Inc. Anticorpo anti-a-syn e uso do mesmo
WO2018129470A1 (fr) 2017-01-09 2018-07-12 The Board Of Trustees Of The Leland Stanford Junior University Inversion de signalisation hedgehog déficiente restaurant la régénération squelettique déficiente
US10350266B2 (en) 2017-01-10 2019-07-16 Nodus Therapeutics, Inc. Method of treating cancer with a multiple integrin binding Fc fusion protein
AU2018207303A1 (en) 2017-01-10 2019-07-25 xCella Biosciences, Inc. Combination tumor treatment with an integrin-binding-Fc fusion protein and immune modulator
EP3568143B1 (fr) 2017-01-11 2023-12-13 Paracelsus Medizinische Privatuniversität Salzburg - Privatstiftung Vésicules extracellulaires dérivées de cellules souches mésenchymateuses et leur utilisation médicale
IL313587A (en) 2017-01-17 2024-08-01 Amgen Inc Method of treating or ameliorating metabolic disorders using glp-1 receptor agonists conjugated to antagonists for gastric inhibitory peptide receptor (gipr)
SMT202500367T1 (it) 2017-02-02 2025-11-10 Amgen Res Munich Gmbh Composizione farmaceutica a basso ph comprendente costrutti di anticorpo che reclutano le cellule t
PE20191716A1 (es) 2017-02-08 2019-12-05 Bristol Myers Squibb Co Polipeptidos de relaxina modificada que comprenden un mejorador farmacocinetico y sus usos
US10335453B2 (en) 2017-03-01 2019-07-02 Nymox Corporation Compositions and methods for improving sexual function
WO2018160791A1 (fr) 2017-03-03 2018-09-07 Massachusetts Institute Of Technology Constructions antimicrobiennes et leurs utilisations
US10421968B2 (en) 2017-03-15 2019-09-24 Versitech Limited Amphiphilic dendrimers complexed with siRNA for treatment of cancer
RU2767410C2 (ru) 2017-03-24 2022-03-17 Интра-Селлулар Терапиз, Инк. Новые композиции и способы
EP3615937B1 (fr) 2017-04-25 2026-01-28 Prothera Biologics, Inc. Procédés de quantification de protéines d'inhibiteur inter-alpha
WO2018203545A1 (fr) 2017-05-02 2018-11-08 国立研究開発法人国立精神・神経医療研究センター Procédé de prédiction et d'évaluation d'un effet thérapeutique dans des maladies associées à il-6 et à des neutrophiles
WO2018202957A1 (fr) 2017-05-04 2018-11-08 Helsingin Yliopisto Fragments cdnf et manf c-terminaux, compositions pharmaceutiques les comprenant et leurs utilisations
UY37726A (es) 2017-05-05 2018-11-30 Amgen Inc Composición farmacéutica que comprende constructos de anticuerpos biespecíficos para almacenamiento y administración mejorados
JP7283699B2 (ja) 2017-05-12 2023-05-30 マックス－プランク－ゲゼルシャフト・ツア・フェルデルング・デア・ヴィッセンシャフテン・エー・ファオ 黒色腫の治療または予防において使用するためのフェニル－ヘテロ環－フェニル誘導体
JOP20190259A1 (ar) 2017-05-31 2019-10-31 Amgen Inc بروتينات ربط مولد ضد مضادة لـ jagged1
US20190062428A1 (en) 2017-06-19 2019-02-28 Surface Oncology, Inc. Combination of anti-cd47 antibodies and cell death-inducing agents, and uses thereof
CA3067890A1 (fr) 2017-06-19 2018-12-27 Talengen International Limited Procede de regulation et controle de glp-1/glp-1r et medicament associe
EA201992502A1 (ru) 2017-06-20 2020-04-22 Эмджен Инк. Способ лечения или уменьшения интенсивности метаболических нарушений с применением белков, связывающих рецептор гастроингибиторного пептида (gipr), в комбинации с агонистами glp-1
EP3642238A1 (fr) 2017-06-21 2020-04-29 Amgen Inc. Méthode de traitement ou d'amélioration des troubles métaboliques à l'aide de protéines de liaison antagonistes pour protéines de fusion agonistes du récepteur du peptide inhibiteur gastrique (gipr)/récepteur glp-1
AU2018301393B2 (en) 2017-07-11 2025-02-27 Compass Therapeutics Llc Agonist antibodies that bind human CD137 and uses thereof
CA3070089A1 (fr) 2017-07-19 2019-01-24 Auckland Uniservices Limited Modulation de cytokine
EP3658144B1 (fr) 2017-07-26 2022-01-26 Intra-Cellular Therapies, Inc. Composés pyridopyrroloquinoxalines, leurs compositions et utilisations en thérapie
WO2019023062A1 (fr) 2017-07-26 2019-01-31 Intra-Cellular Therapies, Inc. Composés organiques
CN111164104A (zh) 2017-08-09 2020-05-15 麻省理工学院 白蛋白结合肽缀合物及其方法
EP3684811A2 (fr) 2017-08-17 2020-07-29 Massachusetts Institute of Technology Agents de liaison à spécificité multiple de chimiokines cxc et leurs utilisations
CA3073537A1 (fr) 2017-08-22 2019-02-28 Sanabio, Llc Recepteurs d'interferon solubles et leurs utilisations
KR20260026092A (ko) 2017-09-19 2026-02-25 메사추세츠 인스티튜트 오브 테크놀로지 키메라 항원 수용체 t 세포 요법을 위한 조성물 및 그의 용도
EP3692061A1 (fr) 2017-10-04 2020-08-12 Amgen Inc. Fusions d'immunoglobulines de transthyrétine
JP7235249B2 (ja) 2017-10-20 2023-03-08 学校法人兵庫医科大学 抗ｉｌ－６受容体抗体を含有する術後の癒着を抑制するための医薬組成物
US11066438B2 (en) 2017-10-30 2021-07-20 Enterin, Inc. Squalamine solid forms and methods of making the same
WO2019089753A2 (fr) 2017-10-31 2019-05-09 Compass Therapeutics Llc Anticorps cd137 et antagonistes pd-1 et leurs utilisations
EP3713961A2 (fr) 2017-11-20 2020-09-30 Compass Therapeutics LLC Anticorps cd137 et anticorps ciblant un antigène tumoral et leurs utilisations
AU2018383679B2 (en) 2017-12-11 2025-10-09 Amgen Inc. Continuous manufacturing process for bispecific antibody products
EP3725806A4 (fr) 2017-12-14 2022-03-30 ABL Bio Inc. Anticorps bispécifique contre a-syn/igf1r et utilisation associée
CN111465408B (zh) 2017-12-15 2023-07-04 泰伦基国际有限公司 一种预防或治疗骨关节炎的方法和药物
JP2021506851A (ja) 2017-12-19 2021-02-22 マサチューセッツ インスティテュート オブ テクノロジー 抗原−アジュバントカップリング試薬および使用の方法
JP7314146B2 (ja) 2017-12-28 2023-07-25 中外製薬株式会社 細胞傷害誘導治療剤
TW201940518A (zh) 2017-12-29 2019-10-16 美商安進公司 針對ｍｕｃ１７和ｃｄ３之雙特異性抗體構建體
WO2019151418A1 (fr) 2018-01-31 2019-08-08 元一 加藤 Agent thérapeutique pour l'asthme contenant un inhibiteur d'il-6
JP7777921B2 (ja) 2018-02-09 2025-12-01 ガルデルマ ホールディング エスエー 中等度から重度の掻破痕を有するアトピー性皮膚炎の治療におけるネモリズマブ
KR20230020023A (ko) 2018-03-14 2023-02-09 서피스 온콜로지, 인크. Cd39에 결합하는 항체 및 이의 용도
WO2019178484A1 (fr) 2018-03-16 2019-09-19 Intra-Cellular Therapies, Inc. Nouveaux procédés
CN112512571B (zh) 2018-03-22 2025-02-07 表面肿瘤学有限责任公司 抗il-27抗体及其用途
CN112040940A (zh) 2018-03-23 2020-12-04 细胞内治疗公司 有机化合物
US20210008065A1 (en) 2018-03-23 2021-01-14 Intra-Cellular Therapies, Inc. Organic compounds
EP4678236A3 (fr) 2018-03-29 2026-04-08 MyNeuroCure Oy Fragments cdnf et manf c-terminaux, compositions pharmaceutiques les comprenant et leurs utilisations
EP3774879B1 (fr) 2018-03-30 2026-01-28 Amgen Inc. Variants d'anticorps anti-c-terminal
CR20200510A (es) 2018-04-09 2020-11-26 Amgen Inc Protreínas de fusión del factor de diferenciación de crecimiento 15
WO2019200357A1 (fr) 2018-04-12 2019-10-17 Surface Oncology, Inc. Biomarqueur pour agents thérapeutiques ciblant cd47 et leurs utilisations
JP7366057B2 (ja) 2018-04-19 2023-10-20 チェックメイト ファーマシューティカルズ， インコーポレイテッド 合成ｒｉｇ－ｉ様受容体アゴニスト
WO2019207051A1 (fr) 2018-04-25 2019-10-31 Università Degli Studi Di Torino Utilisation médicale de combinaisons de sémaphorines 3 et d'antimétabolites non naturels
WO2019226658A1 (fr) 2018-05-21 2019-11-28 Compass Therapeutics Llc Compositions multispécifiques de liaison à l'antigène et procédés d'utilisation
CA3099308A1 (fr) 2018-05-21 2019-11-28 Compass Therapeutics Llc Compositions et procedes pour ameliorer la destruction de cellules cibles par des lymphocytes nk
WO2019225777A1 (fr) 2018-05-23 2019-11-28 에이비엘바이오 주식회사 Anticorps anti-ror1 et son utilisation
WO2019225787A1 (fr) 2018-05-24 2019-11-28 에이비엘바이오 주식회사 Anticorps anti-b7-h3 et son utilisation
EP3801527B1 (fr) 2018-06-08 2025-02-19 Intra-Cellular Therapies, Inc. Gamma-carbolines fusionnées pour le traitement aigu de l'anxiété ou de la dépression
MX2020013450A (es) 2018-06-11 2021-08-11 Univ Florida Materiales y métodos para tratar el cancer y los trastornos relacionados con el estrés.
CA3240552A1 (fr) 2018-06-11 2019-12-19 Intra-Cellular Therapies, Inc. Synthese de gamma-carbolines fusionnees a heterocycles substitues
EP3807644A4 (fr) 2018-06-12 2022-07-06 Angiex, Inc. Conjugués anticorps-oligonucléotide
WO2020011938A1 (fr) 2018-07-11 2020-01-16 Medizinische Universität Wien Glucocorticoïdes pour le traitement topique de la gastrite auto-immune
WO2020018715A1 (fr) 2018-07-17 2020-01-23 Massachusetts Institute Of Technology Protéines de fusion à base d'échafaudage d'immunoglobuline multimère soluble et leurs utilisations
WO2020033923A1 (fr) 2018-08-09 2020-02-13 Compass Therapeutics Llc Agents de liaison à l'antigène qui se lient à cd277 et leurs utilisations
WO2020033925A2 (fr) 2018-08-09 2020-02-13 Compass Therapeutics Llc Anticorps qui se lient à cd277 et leurs utilisations
EP3833442A2 (fr) 2018-08-09 2021-06-16 Compass Therapeutics LLC Anticorps qui se lient à cd277 et leurs utilisations
MX2021002301A (es) 2018-08-28 2021-04-28 Ambrx Inc Bioconjugados de anticuerpo-foliato anti-cd3 y sus usos.
US12144808B2 (en) 2018-08-29 2024-11-19 Intra-Cellular Therapies, Inc. Compositions and methods
WO2020047408A1 (fr) 2018-08-31 2020-03-05 Intra-Cellular Therapies, Inc. Nouvelles méthodes
BR112021003655A2 (pt) 2018-08-31 2021-05-18 Intra-Cellular Therapies, Inc. métodos novos
CA3111576A1 (fr) 2018-09-11 2020-03-19 Ambrx, Inc. Conjugues polypeptidiques d'interleukine-2 et leurs utilisations
WO2020053808A1 (fr) 2018-09-12 2020-03-19 Georg Dewald Procédé de diagnostic de troubles vasorégulateurs
AU2019346335B2 (en) 2018-09-28 2024-07-25 Massachusetts Institute Of Technology Collagen-localized immunomodulatory molecules and methods thereof
JP7644706B2 (ja) 2018-10-11 2025-03-12 アムジエン・インコーポレーテツド 二重特異性抗体コンストラクトの下流プロセシング
JP2022512746A (ja) 2018-10-19 2022-02-07 アンブルックス，インコーポレイテッド インターロイキン－１０ポリペプチド複合体、その二量体、およびそれらの使用
EP3894440A4 (fr) 2018-12-13 2022-09-07 Surface Oncology, Inc. Anticorps anti-il-27 et leurs utilisations
WO2020131899A1 (fr) 2018-12-17 2020-06-25 Intra-Cellular Therapies, Inc. Composé organique
WO2020142740A1 (fr) 2019-01-04 2020-07-09 Resolve Therapeutics, Llc Traitement de la maladie de sjögren à l'aide de protéines de fusion de type nucléases
US11680105B2 (en) 2019-01-17 2023-06-20 Regents Of The University Of Minnesota Antibody fragments for detecting cancer and methods of use
EP3914289A1 (fr) 2019-01-23 2021-12-01 Massachusetts Institute of Technology Schéma posologique de dosage d'immunothérapie combinée pour un blocage de points de contrôle immunitaires
US11236157B2 (en) 2019-01-28 2022-02-01 Galderma Holding SA Treatment of skin lesions and pruritus in prurigo nodularis patients
GB201901305D0 (en) 2019-01-30 2019-03-20 Immunocore Ltd Specific binding molecules
CA3128081A1 (fr) 2019-02-12 2020-08-20 Ambrx, Inc. Contenant de compositions, procedes et utilisations de conjugues anticorps-agonistes tlr
WO2020191305A2 (fr) 2019-03-20 2020-09-24 Massachusetts Institute Of Technology Utilisations d'amphiphiles en thérapie cellulaire immunitaire et compositions associées
WO2020198136A1 (fr) 2019-03-22 2020-10-01 New York Medical College Utilisation de rifaximine sur de vieux neutrophiles circulants dans la drépanocytose
US20220220210A1 (en) 2019-03-29 2022-07-14 Chugai Seiyaku Kabushiki Kaisha Anti-il-6 receptor antibody-containing inhibitor for inhibiting deterioration of bbb function
EP3957324A4 (fr) 2019-04-17 2023-02-08 Hiroshima University Agent thérapeutique pour cancer urologique caractérisé en ce qu'il est administré avec un inhibiteur de il-6 et un inhibiteur de ccr2 en combinaison
CN113795274A (zh) 2019-05-10 2021-12-14 泰伦基国际有限公司 一种治疗肌萎缩侧索硬化的方法和药物
WO2020241816A1 (fr) 2019-05-31 2020-12-03 国立大学法人大阪大学 Nouvel agent thérapeutique contre les cancers digestifs, et méthode de criblage associée
WO2020246563A1 (fr) 2019-06-05 2020-12-10 中外製薬株式会社 Molécule de liaison à un site de clivage d'anticorps
WO2020250915A1 (fr) 2019-06-10 2020-12-17 中外製薬株式会社 Molécule de liaison à l'antigène anti-lymphocytes t à utiliser en association avec un inhibiteur de cytokines
MX2021014644A (es) 2019-06-13 2022-04-06 Amgen Inc Control de perfusion basado en biomasa automatizado en la fabricacion de productos biologicos.
WO2020263399A1 (fr) 2019-06-26 2020-12-30 Massachusetts Institute Of Technology Complexes protéine de fusion-hydroxyde métallique immunomodulateurs et leurs procédés
WO2021007245A1 (fr) 2019-07-07 2021-01-14 Intra-Cellular Therapies, Inc. Nouveaux procédés
EP3997112A1 (fr) 2019-07-08 2022-05-18 Amgen, Inc Fusions d'immunoglobulines de transthyrétine multispécifiques
MX2022000111A (es) 2019-07-10 2022-02-10 Chugai Pharmaceutical Co Ltd Moleculas de union a claudina-6 y usos de las mismas.
AU2020323901A1 (en) 2019-07-26 2022-02-24 Amgen Inc. Anti-IL13 antigen binding proteins
GB201910900D0 (en) 2019-07-31 2019-09-11 Scancell Ltd Modified fc-regions to enhance functional affinity of antibodies and antigen binding fragments thereof
GB201910899D0 (en) 2019-07-31 2019-09-11 Scancell Ltd Binding members
PH12022550326A1 (en) 2019-08-13 2023-03-13 Amgen Inc Interleukin-2 muteins for the expansion of t-regulatory cells
GB201912657D0 (en) 2019-09-03 2019-10-16 Scancell Ltd Binding members
GB201912882D0 (en) 2019-09-06 2019-10-23 Scancell Ltd Ssea-4 binding members
KR20220062500A (ko) 2019-09-16 2022-05-17 서피스 온콜로지, 인크. 항-cd39 항체 조성물 및 방법
MX2022003719A (es) 2019-09-25 2022-04-26 Surface Oncology Inc Anticuerpos anti-il-27 y sus usos.
EP4041281B1 (fr) 2019-10-04 2025-11-26 Amgen Inc. Utilisation de gdf15 pour le traitement du syndrôme cardiométabolique et d'autres maladies
TW202207984A (zh) 2019-10-11 2022-03-01 日商中外製藥股份有限公司 用於後天性血友病a之預防及/或治療之醫藥組成物、及包含該醫藥組成物之製品
JP7707161B2 (ja) 2019-10-23 2025-07-14 チェックメイト ファーマシューティカルズ， インコーポレイテッド 合成ｒｉｇ－ｉ様受容体アゴニスト
US11459389B2 (en) 2019-10-24 2022-10-04 Massachusetts Institute Of Technology Monoclonal antibodies that bind human CD161
CN115551594A (zh) 2019-10-24 2022-12-30 米诺陶治疗公司 经细胞因子修饰的嵌合抗体及其使用方法
US20220396599A1 (en) 2019-11-13 2022-12-15 Amgen Inc. Method for Reduced Aggregate Formation in Downstream Processing of Bispecific Antigen-Binding Molecules
EP4368184A3 (fr) 2019-11-19 2024-07-31 Modag GmbH Nouveaux composés pour le diagnostic, le traitement et la prévention de maladies associées à l'agrégation de l'alpha-synucléine
EP4072554A4 (fr) 2019-12-11 2023-12-20 Intra-Cellular Therapies, Inc. Composé organique
IL293471A (en) 2019-12-17 2022-08-01 Amgen Inc Dual interleukin-2 / tnf receptor agonist for use in medicine
EP3838912A1 (fr) 2019-12-20 2021-06-23 Herantis Pharma Oyj Peptides rétro inverses
EP3838345A1 (fr) 2019-12-20 2021-06-23 Herantis Pharma Oyj Peptides macrocycliques
CA3160204A1 (fr) 2020-01-06 2021-07-15 Vaccinex, Inc. Anticorps anti-ccr8 et leurs utilisations
CN115666621A (zh) 2020-01-13 2023-01-31 度勒科特公司 具有减少的杂质的持续释放药物递送系统及相关方法
KR20220127880A (ko) 2020-01-17 2022-09-20 탈렌젠 인터내셔널 리미티드 신경 손상 및 이의 관련 병증 치료 방법
EP4094775A4 (fr) 2020-02-06 2023-04-19 Talengen International Limited Procédé et médicament pour la prévention et le traitement de la sclérose en plaques
US20230081922A1 (en) 2020-02-11 2023-03-16 Talengen International Limited Method and drug for treating viral pneumonia
WO2021173889A1 (fr) 2020-02-26 2021-09-02 Ambrx, Inc. Utilisations de bioconjugués folate-anticorps anti-cd3
KR20220143913A (ko) 2020-02-26 2022-10-25 탈렌젠 인터내셔널 리미티드 혈압 이상 병증의 예방 및 치료 방법과 약물
AU2021225926A1 (en) 2020-02-26 2022-10-20 Case Western Reserve University Compositions and methods for treating misfolded protein ocular disorders
EP4117732A1 (fr) 2020-03-11 2023-01-18 Ambrx, Inc. Conjugués polypeptidiques d'interleukine-2 et leurs procédés d'utilisation
WO2021188851A1 (fr) 2020-03-19 2021-09-23 Amgen Inc. Anticorps contre la mucine 17 et leurs utilisations
US20230173039A1 (en) 2020-03-24 2023-06-08 Talengen International Limited Method and drug for treating alzheimer disease
CN115697386A (zh) 2020-03-24 2023-02-03 泰伦基国际有限公司 一种治疗帕金森病的方法和药物
EP4122489A4 (fr) 2020-03-24 2023-04-12 Talengen International Limited Méthode et médicament pour favoriser la dégradation d'une protéine mal repliée et d'un agrégat de celle-ci
US20230141921A1 (en) 2020-03-24 2023-05-11 Talengen International Limited Method and medicine for treating huntington's disease
JP2023106635A (ja) 2020-04-17 2023-08-02 中外製薬株式会社 二重特異性抗原結合分子ならびに、それに関連する組成物、組成物の製造のための使用、キット、および方法
US20210340524A1 (en) 2020-05-01 2021-11-04 Massachusetts Institute Of Technology Methods for identifying chimeric antigen receptor-targeting ligands and uses thereof
US12433954B2 (en) 2020-05-01 2025-10-07 Massachusetts Institute Of Technology Methods of activating anti-CD19 chimeric antigen receptor (CAR) T cells using amphiphilic ligand conjugates comprising CAR-targeting protein sequence motifs
EP4140498A4 (fr) 2020-05-11 2023-11-01 Talengen International Limited Procédé et médicament pour le traitement d'une amyotrophie spinale
WO2021248081A1 (fr) 2020-06-05 2021-12-09 The J. David Gladstone Institutes, A Testamentary Trust Established Under The Will Of J. David Gladstone Inhibition du récepteur acvr1 (alk2) pour traiter des maladies neurologiques
GB202101299D0 (en) 2020-06-09 2021-03-17 Avacta Life Sciences Ltd Diagnostic polypetides and methods
MX2022015764A (es) 2020-06-19 2023-01-19 Chugai Pharmaceutical Co Ltd Molecula de union al antigeno anti-celulas t para usarse en combinacion con un inhibidor de angiogenesis.
CA3165342A1 (fr) 2020-06-29 2022-01-06 James Arthur Posada Traitement du syndrome de sjogren a l'aide de proteines de fusion de type nucleases
CN116194124A (zh) 2020-07-31 2023-05-30 中外制药株式会社 包含表达嵌合受体的细胞的药物组合物
WO2022023292A2 (fr) 2020-07-31 2022-02-03 Friedrich-Alexander-Universität Erlangen-Nürnberg Anticorps ciblant la protéine de spicule de coronavirus et leur utilisation
JP2023538071A (ja) 2020-08-20 2023-09-06 アンブルックス，インコーポレイテッド 抗体－ｔｌｒアゴニストコンジュゲート、その方法及び使用
CA3189358A1 (fr) 2020-08-26 2022-03-03 Scancell Limited Acides nucleiques codant pour un polypeptide comprenant une region fc modifiee d'une igg1 humaine et au moins un antigene heterologue
US20230382978A1 (en) 2020-10-15 2023-11-30 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Antibody specific for sars-cov-2 receptor binding domain and therapeutic methods
WO2022087274A1 (fr) 2020-10-21 2022-04-28 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Anticorps qui neutralisent l'activité de l'interféron de type i (ifn)
CR20230229A (es) 2020-11-06 2023-09-05 Amgen Res Munich Gmbh Moléculas de unión a antígeno biespecíficas con múltiples dianas de selectividad aumentada
CN116669757A (zh) 2020-11-17 2023-08-29 泰伦基国际有限公司 一种提高bdnf水平的方法和药物
CN116490200A (zh) 2020-11-17 2023-07-25 泰伦基国际有限公司 一种提高ngf水平的方法和药物
CA3203561A1 (fr) 2021-01-12 2022-07-21 Adrian Neil Verity Systemes d'administration de medicament a liberation prolongee et procedes associes
CN117321076A (zh) 2021-02-19 2023-12-29 美国卫生及公众服务部代表 中和SARS-CoV-2的单结构域抗体
IL305793A (en) 2021-03-12 2023-11-01 Hoffmann La Roche A pharmaceutical preparation for the treatment or prevention of myasthenia gravis
CA3213805A1 (fr) 2021-04-03 2022-10-06 Feng Tian Conjugues anticorps-medicament anti-her2 et leurs utilisations
US20250197525A1 (en) 2021-04-28 2025-06-19 Minotaur Therapeutics, Inc. Humanized chimeric bovine antibodies and methods of use
JP2024518369A (ja) 2021-05-06 2024-05-01 アムジェン リサーチ （ミュニック） ゲゼルシャフト ミット ベシュレンクテル ハフツング 増殖性疾患で使用されるｃｄ２０及びｃｄ２２標的化抗原結合分子
WO2022236134A1 (fr) 2021-05-07 2022-11-10 Surface Oncology, Inc. Anticorps anti-il-27 et leurs utilisations
EP4574211A3 (fr) 2021-05-14 2025-09-10 Claris Biotherapeutics, Inc. Compositions de facteur de croissance pour le traitement de maladies oculaires
TW202323276A (zh) 2021-09-03 2023-06-16 瑞士伯恩大學 用於治療長qt症候群之組成物及方法
WO2023053282A1 (fr) 2021-09-29 2023-04-06 中外製薬株式会社 Agent thérapeutique induisant la cytotoxicité destiné à être utilisé dans le traitement du cancer
IL312515A (en) 2021-11-03 2024-07-01 Affimed Gmbh Bispecific cd16a binders
US20260070986A1 (en) 2021-11-03 2026-03-12 Affimed Gmbh Bispecific cd16a binders
KR102707065B1 (ko) 2022-03-08 2024-09-19 동국제약 주식회사 코아세르베이션법을 이용하여 현탁성이 개선된 미립구의 제조방법
AU2023255339A1 (en) 2022-04-19 2024-12-05 Sasha A. PHILBERT Treatment of brain copper disorders
EP4522651A1 (fr) 2022-05-12 2025-03-19 Amgen Research (Munich) GmbH Molécules bispécifiques multicibles à chaînes multiples de liaison à un antigène à sélectivité accrue
CN119486738A (zh) 2022-05-18 2025-02-18 细胞内治疗公司 新方法
US12414948B2 (en) 2022-05-18 2025-09-16 Intra-Cellular Therapies, Inc. Methods
US20240026001A1 (en) 2022-05-25 2024-01-25 Surface Oncology, Inc. Use of anti-il-27 antibodies
US20240025987A1 (en) 2022-05-25 2024-01-25 Surface Oncology, Inc. Use of anti-il-27 antibodies
WO2023243689A1 (fr) 2022-06-16 2023-12-21 国立大学法人大阪大学 Nouvel agent de traitement de maladie inflammatoire et procédé de dépistage pour celui-ci
WO2024047497A1 (fr) 2022-09-02 2024-03-07 Galderma Holding SA Traitements de prurigo nodularis
AR130384A1 (es) 2022-09-02 2024-12-04 Univ Of Bern Composiciones y métodos para tratar el síndrome de qt largo
TW202421650A (zh) 2022-09-14 2024-06-01 美商安進公司 雙特異性分子穩定組成物
WO2024076995A1 (fr) 2022-10-03 2024-04-11 Insigna Inc. Compositions pour la prévention non chirurgicale de l'odeur et du comportement agressif
CN120322559A (zh) 2022-10-18 2025-07-15 株式会社Nb健康研究所 抗体、核酸、细胞和药物
KR20250096849A (ko) 2022-11-04 2025-06-27 탈렌젠 인터내셔널 리미티드 병리학적 tdp-43 단백질의 분해를 촉진하는 방법 및 약물
EP4613285A4 (fr) 2022-11-04 2025-11-05 Talengen Int Ltd Procédé et médicament pour favoriser l'élimination de protéines pathologiques par système protéasome-ubiquitine et système lysosomal autophagique
EP4630537A1 (fr) 2022-12-07 2025-10-15 Fondazione Matilde Tettamanti e Menotti de Marchi Onlus Procédés de génération de cellules tueuses induites par des cytokines génétiquement modifiées (cik)
CN115804830B (zh) * 2022-12-16 2024-08-20 浙江圣兆药物科技股份有限公司 一种缩短迟滞期的戈舍瑞林缓释植入剂
WO2024145659A1 (fr) 2022-12-30 2024-07-04 Intra-Cellular Therapies, Inc. Gamma-carbolines hétérocycliques fusionnées agissant sur le récepteur 5-ht2a de la sérotonine
WO2024173901A1 (fr) 2023-02-17 2024-08-22 Intra-Cellular Therapies, Inc. Lumatépérone et ses dérivés pour moduler le système nerveux
KR20250149177A (ko) 2023-02-21 2025-10-15 조인트-스톡 컴퍼니 "제네리움" 제2형 점액다당류증을 앓고 있는 대상체의 리소좀 효소 결핍을 예방 및 치료하기 위한 약제학적 조성물 및 방법
AU2024247601A1 (en) 2023-03-28 2025-10-23 Nb Health Laboratory Co., Ltd. Antibody, nucleic acid, cell and drug
TW202444922A (zh) 2023-03-31 2024-11-16 國立大學法人大阪大學 用於預測敗血症患者之預後的生物標記及其用途
AU2024308069A1 (en) 2023-06-27 2026-02-05 Firecyte Therapeutics, Inc. Insulin-like growth factor binding protein like 1 (igfbpl1) compositions and methods of use thereof
WO2025111568A1 (fr) 2023-11-22 2025-05-30 Intra-Cellular Therapies, Inc. Lumatépérone et analogues, modulateurs du récepteur 5-ht2a ou 5-ht2a/d2, destinés à être utilisés dans le traitement de troubles psychiatriques provoqués par l'encéphalite virale, bactérienne ou auto-immune, et de symptômes psychiatriques de ceux-ci
WO2025147696A1 (fr) 2024-01-05 2025-07-10 Resolve Therapeutics, Llc Traitement de symptômes associés à une infection virale au sars-cov ou à une infection virale au sars-cov antérieure avec des agents nucléasiques
WO2025155602A1 (fr) 2024-01-16 2025-07-24 Genentech, Inc. Méthode de traitement de l'hémophilie a
WO2025191291A1 (fr) 2024-03-14 2025-09-18 Universidad Complutense De Madrid Méthodes de prévention ou de traitement d'un dysfonctionnement érectile (de) par administration de slpi (inhibiteurs de protéase leucocytaire sécrétoire)
WO2025198912A1 (fr) 2024-03-21 2025-09-25 Hoffmann-La Roche Inc. Méthodes de traitement de la myasthénie grave
WO2025226603A1 (fr) 2024-04-22 2025-10-30 Surface Oncology, LLC Méthodes de traitement d'un cancer à l'aide d'anticorps anti-ccr8
WO2025257588A1 (fr) 2024-06-10 2025-12-18 Affimed Gmbh Liant polyspécifique d'antigène de cd16a/tumeur destiné à être utilisé dans le traitement de la résistance à un inhibiteur de point de contrôle immunitaire
WO2026011136A1 (fr) 2024-07-03 2026-01-08 Intra-Cellular Therapies, Inc. Composés organiques
WO2026011166A1 (fr) 2024-07-03 2026-01-08 Intra-Cellular Therapies, Inc. Hétérocycles substitués destinés à être utilisés dans le traitement de maladies impliquant le récepteur 5-ht2a
WO2026050206A1 (fr) 2024-08-27 2026-03-05 Ironwood Pharmaceuticals, Inc. Combinaisons d'agonistes du récepteur de glp-1 et de guanylate cyclase c (gc-c)
WO2026055167A1 (fr) 2024-09-05 2026-03-12 Surface Oncology, LLC Anticorps anti-il-27 et utilisation de biomarqueurs dans leurs utilisations
WO2026055168A1 (fr) 2024-09-06 2026-03-12 Surface Oncology, LLC Anticorps anti-il-27, leurs utilisations et doses

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3887699A (en) * 1969-03-24 1975-06-03 Seymour Yolles Biodegradable polymeric article for dispensing drugs
US3773919A (en) * 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US3839297A (en) * 1971-11-22 1974-10-01 Ethicon Inc Use of stannous octoate catalyst in the manufacture of l(-)lactide-glycolide copolymer sutures
JPS5324423B2 (fr) * 1972-04-29 1978-07-20
JPS5017525A (fr) * 1973-06-14 1975-02-24
JPS5035158A (fr) * 1973-07-24 1975-04-03
JPS5749532B2 (fr) * 1974-03-19 1982-10-22
JPS5314072B2 (fr) * 1973-09-29 1978-05-15
JPS5726506B2 (fr) * 1974-03-08 1982-06-04
US3976071A (en) * 1974-01-07 1976-08-24 Dynatech Corporation Methods of improving control of release rates and products useful in same
NZ181036A (en) * 1975-06-12 1978-12-18 A Schally Luteinising hormone releasing hormone analogues and intermediates therefor
US4011312A (en) * 1975-06-25 1977-03-08 American Home Products Corporation Prolonged release drug form for the treatment of bovine mastitis
US4010196A (en) * 1975-06-25 1977-03-01 American Home Products Corporation Linear polyester salts
CA1123984A (fr) * 1977-11-16 1982-05-18 Yuzi Okuzumi Copolymeres sequences de lactide et de glycolide et protheses chirurgicales
US4234571A (en) * 1979-06-11 1980-11-18 Syntex (U.S.A.) Inc. Nonapeptide and decapeptide derivatives of luteinizing hormone releasing hormone
AU534665B2 (en) * 1979-09-12 1984-02-09 Eli Lilly And Company Method
US4333919A (en) * 1979-09-12 1982-06-08 Eli Lilly And Company Growth promotant controlled release formulations and method of treatment
US4331652A (en) * 1979-09-12 1982-05-25 Eli Lilly And Company Controlled release parasitic formulations and method
US4293539A (en) * 1979-09-12 1981-10-06 Eli Lilly And Company Controlled release formulations and method of treatment
US4273920A (en) * 1979-09-12 1981-06-16 Eli Lilly And Company Polymerization process and product
PH19942A (en) * 1980-11-18 1986-08-14 Sintex Inc Microencapsulation of water soluble polypeptides
IE52535B1 (en) * 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions

Also Published As

Publication number Publication date
JPS57150609A (en) 1982-09-17
PT74434A (en) 1982-03-01
HU186904B (en) 1985-10-28
JPH0157098B2 (fr) 1989-12-04
MY101545A (en) 1991-12-17
NZ199732A (en) 1985-08-30
JPH031330B2 (fr) 1991-01-10
JPH0774143B2 (ja) 1995-08-09
AU582920B2 (en) 1989-04-13
HK107890A (en) 1990-12-28
DK59182A (da) 1982-08-17
NO162103C (no) 1992-03-04
GR76791B (fr) 1984-09-04
EP0058481B2 (fr) 2003-05-21
ATE22535T1 (de) 1986-10-15
JPH05221871A (ja) 1993-08-31
EP0058481A1 (fr) 1982-08-25
US4767628B1 (fr) 1990-07-17
JPS6264824A (ja) 1987-03-23
US5004602A (en) 1991-04-02
FI820467L (fi) 1982-08-17
YU44066B (en) 1990-02-28
AU2840789A (en) 1989-05-04
YU31582A (en) 1985-04-30
JPH05271051A (ja) 1993-10-19
ES509647A0 (es) 1983-08-01
HU199695B (en) 1990-03-28
IE52535B1 (en) 1987-12-09
IE820165L (en) 1982-08-16
NO162103B (no) 1989-07-31
US4767628A (en) 1988-08-30
NO820433L (no) 1982-08-17
AU560829B2 (en) 1987-04-16
JPH0686390B2 (ja) 1994-11-02
ES8307845A1 (es) 1983-08-01
AU7998682A (en) 1982-08-26
CA1169090A (fr) 1984-06-12
DE3273501D1 (en) 1986-11-06
AU6498886A (en) 1987-02-19
ZA82565B (en) 1982-10-27
AU602623B2 (en) 1990-10-18
PT74434B (en) 1983-07-14
FI80594B (fi) 1990-03-30
EP0058481B1 (fr) 1986-10-01

Similar Documents

Publication Publication Date Title
DK164845B (da) Farmaceutiske midler omfattende polypeptider med kontinuerlig frigoerelse
US5366734A (en) Continuous release pharmaceutical compositions
US4130639A (en) Absorbable pharmaceutical compositions based on isomorphic copolyoxalates
US3773919A (en) Polylactide-drug mixtures
Youxin et al. In-vitro degradation and bovine serum albumin release of the ABA triblock copolymers consisting of poly (L (+) lactic acid), or poly (L (+) lactic acid-co-glycolic acid) A-blocks attached to central polyoxyethylene B-blocks
EP0302582B1 (fr) Système pour la libération de drogues et son mode de préparation
Avgoustakis Polylactic-co-glycolic acid (PLGA)
JP4170399B2 (ja) ホスフェートによって鎖延長化された生分解性ポリマー、組成物、物品、並びにその製造及び使用方法
US6703477B2 (en) Acid end group poly(D,L-lactide-co-glycolide) copolymers with high glycolide content
US4186189A (en) Absorbable pharmaceutical compositions based on poly(alkylene oxalates)
HUT59943A (en) Process for producing biodecomposable polymeres of high molecular weight and injectable retard microcapsules containing former polymeres
DK165458B (da) Farmaceutisk eller veterinaert acceptabel, amphipatisk, ikke-tvaerbundet, lineaer, forgrenet eller podeblokcopolymer og fremgangsmaade til fremstilling af denne,matrix til brug i et laegemiddel til frigivelse af syrestabile polypeptider omfattende copolymeren samt farmaceutisk middel til parenteral administration omfattende et farmakologisk nyttigt polypeptid og omfattende copolymeren
SK143494A3 (en) Salts of peptides with carboxy-group terminated polyesters and method of their preparation
GB2165454A (en) Pharmaceutical depot forms containing bromocriptine
WO1997042987A1 (fr) Composition et procede pour former des implants biodegradables in situ et utilisations de ces implants
JP2002526396A (ja) 生分解性テレフタレートポリエステル−ポリホスホネートとポリエステル−ポリホスファイトの組成物、物品、及びそれらの使用方法
JP2716747B2 (ja) 薬剤の放出を制御するためのポリエステルを主成分とする薬剤組成物
DK174120B1 (da) Poly(lactid-co-glycol)polymer omfattende mindst 25 mol% mælkesyreenheder og op til 75 mol% glycosyreenheder samt fremgangsmåde til fremstilling heraf
Hutchinson et al. Biodegradable polymers for sustained release of polypeptides
Hutchinson et al. Pharmaceutical Department and Research Department Imperial Chemical Industries PLC, Pharmaceuticals Division Mereside, Alderley Park Macclesfield, Cheshire SK1O 4TG, UK
HK1007490B (en) Drug delivery system and method of making the same

Legal Events

Date Code Title Description
PUP Patent expired